



PROF. DR. MARIANO PROVENCIO PULLA, M.D.,PHD.

Current positions

Head of the Oncology Department at the Puerta de Hierro University Hospital
Professor of Medicine at the Autonomous University of Madrid (UAM)
President of the Spanish Lung Cancer Group (GECP)
President of the Oncology Group for the Treatment and Study of Lymphomas (GOTEL)
Adjunct Professor of Medicine at The George Washington University School of Medicine and Health Sciences
Scientific Director of the Puerta de Hierro Health Research Institute (IDIPHISA)

Madrid, Spain
February, 2025

Content

1. Biography	2
2. About Spanish Lung Cancer Group (Fundación GECP).....	6
3. Biosketch	8
4. Publications from the last 5 years	15

1. Biography Prof. Dr. Mariano Provencio Pulla, M.D., PhD.

Dr. Mariano Provencio stands out for his active and continuous leadership in both independent and collaborative clinical and translational research, leading projects that have significantly contributed to the understanding and management of lung cancer. A series of high impact achievements define Dr. Provencio's multifaceted career:

1. Global Standard Change in Lung Cancer Treatment for Locally Advanced Stages

Dr. Provencio has been responsible for changing the global standard of care for lung cancer treatment in locally advanced stages—a clinical scenario that had seen no progress for the last 30 years. One of the greatest aspirations of any clinician is to develop research that transforms the lives of patients worldwide. Dr. Provencio, together with the GECP, has achieved this milestone.

The development of the NADIM^{1,2,3} project, authored by Dr. Provencio, represents a pioneering work that has set a landmark in clinical oncology and transformed the approach to treating patients with locally advanced non-small cell lung cancer. This clinical trial successfully and innovatively introduced the neoadjuvant chemoimmunotherapy approach (prior to surgery), significantly increasing the feasibility of surgical oncological treatment and doubling the historical survival rate of patients. This advancement has turned a once-fatal disease into one with a potential cure, leading to its inclusion in international lung cancer treatment guidelines⁴. Before Dr. Provencio's approach, the three-year mortality rate for these patients was 70%. Today, 77% of them remain alive and disease-free five years after diagnosis.

The importance of these findings was recognized early by the international scientific community⁵, as reflected in the publication in *Science*⁶ in 2020. The NADIM study has received over 1,900 citations since its initial publication in 2020, with subsequent translational and clinical publications accumulating over 2,190 citations. These citations stem from derivative clinical trials, such as CM816, and international treatment guidelines developed in just four years. Since publication of NADIM study, it has been replicated globally and has formed the foundation for additional research. In fact, due to his expertise, Dr. Provencio served as the senior author of the registration studies that led to regulatory approvals by the FDA (in 2022) and EMA (in 2023).

In December 2024, the Spanish newspapers *El Mundo* and *Diario Médico* recognized the NADIM study as one of the most significant medical advances of the year. Additionally, the five-year follow-up publication of the study's initial results received special recognition from *Nature Reviews*⁷ in 2025.

2. Active and Ongoing Leadership in Clinical and Translational Research

Beyond the NADIM study, Dr. Provencio has led and participated in numerous research projects that have significantly contributed to the understanding and management of lung cancer and lymphomas. His most notable achievements include:

- Over 506 publications in indexed scientific journals, strengthening the scientific evidence base in oncology and improving clinical practice and available treatments. The vast majority stem from independent academic research rather than pharmaceutical industry initiatives, allowing him to serve as the lead or senior author in more than 60% of his articles.
- More than 32,100 citations and a h-index of 73 and h10-index of 292 on Google Scholar.
- Principal Investigator in 30 competitive public research projects.
- Author of 71 books or book chapters on oncology approaches and treatments.
- Extensive contributions to education and updates in lung cancer, including participation in over 436 national and international conferences and providing open and altruistic scientific updates to the medical community.
- The only Spanish researcher serving on the Scientific Program Committee for lung cancer at ASCO (American Society of Clinical Oncology), the world's most prestigious oncology association.
- His ability to lead multidisciplinary teams and foster collaboration between research centers and hospitals has established him as a leading figure in lung cancer research in Spain. In 2014, Dr. Mariano Provencio was democratically elected by his peers as President of the Spanish Lung Cancer Group (GECp), a position he has held uninterruptedly since then. Through this role, he has strengthened the organization's commitment to independent clinical research.

Notably, Dr. Provencio spearheaded the creation of the first national epidemiological registry for lung cancer in Spain, which currently includes more than 34,500 registered patients. Additionally, he led the establishment of the first national observatory dedicated to studying genetic markers in non-small cell lung cancer (NSCLC), further advancing precision oncology in the field.

- Dr. Provencio also serves as the Coordinator of the Oncology and Hematology Department at IDIPHISA and Director of the Translational Lung Cancer Research Group at Puerta de Hierro-Majadahonda University Hospital. This multidisciplinary research group, part of the Institute for Health Research, comprises 36 team members, including 13 senior researchers, 8 postdoctoral fellows, 5 doctoral students, 9 technicians, and 1 administrative staff member. The group is internationally recognized for its scientific excellence and has achieved the highest acquisition of competitive national public research funding (€559,824.70 in 2024) as well as the highest European public funding acquisition (€1,113,695 over the past five years). Notably, Dr. Provencio became the first European principal coordinator of an H2020 project at IDIPHISA. Additionally, Dr. Provencio has played a key role in multiple European H2020 projects and has achieved the highest revenue from clinical trials (€2,376,984.22 in 2023 and over €2 million in 2024). He has also attained the highest cumulative impact factor (730.4 FIA in 2023), the highest number of scientific publications (80 in 2023), the highest number of

patents (1 active and 5 pending applications), and has demonstrated exceptional teaching and talent recruitment capabilities, having hired 30 new researchers in 2023/2024.

- Furthermore, he holds 6 registered patents, further solidifying his contributions to the advancement of oncological research and innovation.

3. Excellence in Clinical and Academic Fields

Clinical Practice

Dr. Provencio has dedicated his clinical practice exclusively to the public healthcare system. As a direct result of his research, more than 30,000 patients in Spain now benefit annually from a paradigm shift in therapeutic strategies that have radically improved survival outcomes.

Since February 2011, Dr. Provencio has served as Head of the Medical Oncology Department at Puerta de Hierro-Majadahonda University Hospital, a position he attained through public competitive examination. He has been repeatedly recognized as one of Spain's top oncologists in multiple editions of Best Doctors by Forbes⁸ and the Monitor de Reputación Sanitaria⁹ rankings.

Under his leadership, the Medical Oncology Department has received numerous prestigious national and international accreditations:

- Designated as an Integrated Oncology and Palliative Care Center by ESMO (2014, reaccruited in 2017, 2020, and 2023).
- Certified by the American Society of Clinical Oncology (ASCO) with the "Quality Oncology Practice Initiative (QOPI)" certification (2022-2025).
- Recognized as the Best Medical Oncology Department in Spain for two consecutive years in the "Best in Class" (BiC) Awards (2022-2023).

Academia and Research Management

- Full Professor of Medical Oncology at the Faculty of Medicine, Autonomous University of Madrid (UAM) (appointment officially published in the Spanish Official Gazette (BOE) on December 1, 2022) and Associate Professor at the same institution since 2011. Recognized for five research evaluation periods ("sexenios"), [1990-1995, 1996-2001, 2002-2007, 2008-2013, 2013-2019] and two teaching excellence evaluation periods ("quinquenios docentes"), [2011-2017, 2017-2022].
- Director of 22 doctoral theses, all awarded *cum laude* distinction.
- Corresponding Academician of the Spanish Royal National Academy of Medicine since 2017.
- Scientific Director of the Puerta de Hierro-Segovia de Arana Health Research Institute (IDIPHISA) since its establishment on October 18, 2012. Under his leadership, the institute was accredited by the Carlos III Health Institute (ISCIII) in 2014, with renewal of accreditation in May 2019.

- Editor-in-Chief of *Clinical and Translational Oncology* (Q2 in Oncology) since 2023.
- International training at top institutions, including Memorial Sloan-Kettering Cancer Center (New York), Paul Brousse Hospital (Paris), MD Anderson Cancer Center (Houston), and Lee-Moffitt Cancer Center (Tampa). Since 2019, he has been an Associate Professor of Medicine at The George Washington University.

[1] Provencio M, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. *Lancet Oncol.* 2020 Nov;21(11):1413-1422.

[2] Provencio M, et al. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer. *N Engl J Med.* 2023 Aug 10;389(6):504-513.

[3] Provencio M, et al. Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial. *Lancet Oncol.* 2024 Nov;25(11):1453-1464.

[4] Spicer JD, et al. Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer. *J Thorac Oncol.* 2024 Oct;19(10):1373-1414.

[5] Chaft JE. Emerging data on induction immunotherapy for NSCLC. *IASLC News-Lung Cancer.* March 2019.

[6] Topalian SL, et al. Neoadjuvant checkpoint blockade for cancer immunotherapy. *Science.* 2020 Jan 31;367(6477):eaax0182.

[7] Cascone T, William WN Jr. Perioperative nivolumab results in favourable long-term outcomes in patients with locally advanced resectable non-small-cell lung cancer. *Nat Rev Clin Oncol.* 2025 Feb;22(2):81-82.

[8] Best Doctor in Spain 2020. Forbes Books.

[9] <https://www.abc.es/salud/enfermedades/diez-mejores-oncologos-espanoles-elegidos-especialistas-cancer-20250120160144-nt.html#vca=compartirrrss&vso=abc&vmc=rrss&vli=fixed-twitter>

2. About Spanish Lung Cancer Group (Fundación GECP)

Dr. Mariano Provencio was elected President of the Spanish Lung Cancer Group (GECP) in 2014. Since then, he has significantly strengthened the group's commitment to independent clinical research. The GECP comprises 196 Spanish hospitals and 710 specialists from various disciplines related to the treatment of lung cancer, including oncology, pulmonology, thoracic surgery, radiation oncology, epidemiology, molecular biology and pathology, among others. Moreover, GECP is placed in a notable position among the scientific and medical community, and it is one of the most active working groups at national and international level in the field of lung cancer.

Over the past 10 years, more than 50 independent research projects have been launched within GECP, covering all aspects of lung cancer pathology and involving over 65,000 patients during this time. The first major study initiated during this period was the NADIM trial, focused on preoperative chemo-immunotherapy. This was the first clinical trial worldwide to explore this approach.

Additionally, among the most notable achievements are:

- Spain's first national epidemiological registry for lung cancer was established in August 2016, now encompassing more than 34,500 registered patients. This registry serves as a comprehensive and representative database of thoracic tumor epidemiology in Spain, integrating clinical and histological data, diagnoses, treatments administered, and prognostic factors. Due to the depth, quality, and scope of the collected data, this registry has become an invaluable resource for understanding lung cancer pathology in Spain. It not only provides critical insights into the current landscape of the disease but also serves as a catalyst for high-impact research and internationally recognized publications, shaping the future of lung cancer management worldwide.
- In addition, GECP launched the ATLAS Project, a pioneering initiative aimed at studying genetic markers in non-small cell lung cancer (NSCLC) patients. This initiative empowers participating centers by providing them with real-time access to molecular data, enabling the selection of the most effective, personalized treatment strategies for each lung cancer patient. The ATLAS Project not only enhances patient access to targeted therapies but also strengthens the universalization of precision medicine across Spain. In collaboration with RTT, the GECP aims to establish the National Observatory of Lung Cancer, housing the largest clinical and molecular database of lung cancer in Spain. This database will serve as an essential resource for advancing the scientific understanding of lung cancer, while also offering valuable social and public health insights, ultimately improving patient outcomes and shaping the future of lung cancer treatment.

Many of its groundbreaking clinical trial results have been published in leading international journals, solidifying its position at the forefront of lung cancer research worldwide.

This extensive research activity has led GECP to achieve a remarkable scientific impact, both in quantity and quality of its publications:

- 500 presentations at national and international conferences.
- 168 publications in top-tier oncology journals, including: *New England Journal of Medicine*, *Lancet Oncology*, *JAMA Oncology*, *European Journal of Cancer*, *Clinical Cancer Research*, *Journal of Clinical Oncology*, *Journal for Immuno Therapy of Cancer*, among others.

The high relevance and influence of these publications have firmly established the GECP at the forefront of lung cancer research worldwide, significantly advancing scientific knowledge. Moreover, they have played a decisive role in transforming clinical practice, directly influencing patient care and treatment approaches on a global scale.

Beyond research, Dr. Provencio's presidency has also strengthened education and dissemination efforts within the GECP, aiming to provide specialized training and knowledge updates on the latest advancements in lung cancer. The GECP regularly organizes and hosts a variety of scientific meetings with a multidisciplinary approach, which have become well-established forums for collaboration among professionals involved in lung cancer management. More than 1,000 specialists benefit from these initiatives annually.

Furthermore, Dr. Provencio has reinforced the group's commitment to social responsibility and public health initiatives, focusing on early detection, prevention, and public awareness. Under his leadership, GECP has developed and implemented multiple strategic initiatives, including social media outreach, public awareness campaigns, anti-tobacco initiatives, public lobby and support to patient associations. These actions have strengthened public engagement, policy influence, and patient support.

3. Biosketch Prof. Dr. Mariano Provencio Pulla, M.D., PhD.

POSITION TITLE

Chief Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda (Madrid, Spain)

EDUCATION/CERTIFICATIONS AND TRAINING

Degree in Medicine - University of Alcalá (Madrid, Spain) [1987]

PhD. in Medicine - University of Alcalá (Madrid, Spain) [1999]

Europe Board Certified Medical Oncology (Paris, France) [1995]

Master in Clinical Management and Specialized Care - Instituto Europeo de Salud y Bienestar Social (Madrid, Spain) [2009]

PROFESSIONAL ACTIVITY

Full Professor, Faculty of Medicine, Universidad Autonoma de Madrid [2011-Present]

Chief Medical Oncology Department, Puerta de Hierro University Hospital [2011-Present]

Adjunct Professor of Medicine, George Washington University [2019 – Present]

President of the Spanish Lymphoma Oncology Group (GOTEL) [2007 – Present]

Corresponding Academic, Royal National Academy of Medicine [2017 – Present]

President of the Spanish Lung Cancer Group (SLCG, Fundación GECP) [2014-Present]

Scientific Director, Puerta de Hierro Institute for Biomedical Research (IDIPHISA) Oncology & Hematology Research Group Leader, IDIPHISA [2012-Present]

Medical Oncologist Attending Physician, Medical Oncology Department, Puerta de Hierro University Hospital [1994 – 2011]

RESEARCH METRICS

Publications	506
National	79
International	427
Contribution to Clinical Practice Guideline	11
h-index (Google Scholar)	73
Total Citations	>32,100
Books & Book Chapters	
Total Book Chapters	71
Conference Contributions	

Total Conference Papers	584
Invited Talks & Keynote Lectures	
Total Invited Lectures	433
PhD Supervision	
Total PhD Theses Supervised	22
Competitive Research Projects	
Total Competitive Research Projects	35
Intellectual Property	
Trademarks and Patents	7

Nº ORCID: <https://orcid.org/0000-0001-6315-7919>

Dr. Provencio at [PubMed](#)

Dr. Provencio at [Google Scholar](#)

MEMBERSHIPS

Sociedad Española de Oncología Médica (SEOM).

European Society of Medical Oncology (ESMO).

American Society of Clinical Oncology (ASCO), Scientific Program Committee.

International Extranodal Study Lymphoma Group (IESLG).

Grupo de Tratamiento de Tumores Digestivos (TTD).

Grupo Español de Investigación en Cáncer de Mama (GEICAM) Foundation.

AME Lung Cancer Collaborative Group of Society of Translational Medicine [2004-2023].

Sociedad Española de Inteligencia Artificial en Biomedicina.

INTERNATIONAL CLINICAL ROTATIONS IN HOSPITAL CENTERS

Clinical Observer at **Memorial Sloan-Kettering Cancer Center**, New York, USA (July – September 2003).

Rotation at **Hospital Paul Brousse**, Villejuif, Paris, France (September 2004).

Clinical Observer at **MD Anderson Cancer Center**, University of Houston, Texas, USA – Lymphoma/Myeloma Department (December 2006 – January 2007).

Rotation at **Moffitt Cancer Center**, Tampa, Florida, USA – Malignant Hematology Department (July 1 – August 30, 2009).

Clinical Observer at **MD Anderson Cancer Center**, University of Houston, Texas, USA – Lymphoma/Myeloma Department (July 2013).

AWARDS AND RECOGNITIONS

- **First Prize ONVIDA** at the 3rd SEOM Symposium.
- **First Prize Albert Jovell** for the most outstanding institutional career in Oncology, awarded by GEPAC (June 2016).
- **National Medicine Award "Cultura Viva"**, 25th edition, Madrid (November 7, 2016).
- **Albert Jovell Award**, 5th Edition, category: Most Outstanding Healthcare Professional in the Field of Oncology, awarded by the Spanish Cancer Patients Group (GEPAC) (April 6, 2017).
- **Award from the Royal Academy of Medicine of Spain** (2017).
- **Appointed Corresponding Academician** of the Royal Academy of Medicine (December 2017).
- **III GÉTICA's Research Article Award 2023** for the article "*Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer*", awarded by the Spanish Group for Immuno-Biological Therapies in Cancer.
- **1st Prize BEST IN CLASS 2023** for *Best Medical Oncology Department*, awarded by the Chair of Innovation and Healthcare Management of Rey Juan Carlos University.
- **Special Award for the Best Spanish Scientific Publication in Oncology** for the *NADIM II study*, Principal Investigator: Mariano Provencio, awarded at the 11th ECO Awards 2023.
- **Top 5 Most Reputable Oncology Specialists in Spain**, awarded at the **2023 Healthcare Leadership and Reputation Awards**, Monitor de Reputación Sanitaria.

MOST RECENT COMPETITIVE PROJECTS

- ❖ EU funded projects:
 - UNCAN-Connect: Decentralized Collaborative Network for Advancing Cancer Research and Innovation (101215206)
 - CLARIFY Cancer Long Survivors Artificial Intelligence Follow Up (875160)
 - P-4LUCAT Personalized medicine for lung cancer treatment: using Big Data-driven approaches for decision support (PERME19002RODR)
 - BigMedilytics. Big Data for Medical Analytics (780495)
 - IASIS Integration and analysis of heterogeneous big data for precision medicine and suggested treatments for different types of patients (727658)
- ❖ National funded projects:
 - Clinical validation in liquid biopsy of a genetic and epigenetic signature as a prognostic tool against chemoimmunotherapy in lung cancer patients (CPP2022-009545)
 - Chemoimmunotherapy in locally advanced stages of NSCLC: validation of ctDNA-derived markers and the tumor microenvironment (PI22/01223)
 - Tumor immune microenvironment and identification of biomarkers of response to neoadjuvant chemotherapy or chemoimmunotherapy in patients with non-small cell lung

cancer (PI19/01652)

- BLIO. Development of molecular markers in liquid biopsy for long survival in oncoimmunotherapy (RTC2019-007359-1)
- INmunoSIGH. Immunological and molecular characterization in liquid biopsy of lung cancer patients for immunotherapy (RTC-2017-6502-1).

THE 20 MOST RELEVANT PUBLICATIONS (LAST 5 YEARS)

1. **PROVENCIO M**, Nadal E, Insa A, García Campelo R, Casal J, Dómine M et al. Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial. *Lancet Oncol*. 2024;25(11):1453–1464.
Number of Citations: 4.
Decile 1.
2. Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, Tanaka F, Taube JM, Cornelissen R, Havel L, Karaseva N, Kuzdzal J, Petruzella LB, Wu L, Pujol JL, Ito H, Ciuleanu TE, de Oliveira Muniz Koch L, Janssens A, Alexandru A, Bohnet S, Moiseyenko FV, Gao Y, Watanabe Y, Coronado Erdmann C, Sathyanarayana P, Meadows-Shropshire S, Blum SI, **PROVENCIO PULLA M**; CheckMate 77T Investigators. Perioperative Nivolumab in Resectable Lung Cancer. *N Engl J Med*. 2024;390(19):1756–1769.
Number of Citations: 104.
Decile 1.
3. Spicer JD, Cascone T, Wynes MW, Ahn MJ, Dacic S, Felip E, Forde PM, Higgins KA, Kris MG, Mitsudomi T, **PROVENCIO M**, Senan S, Solomon BJ, Tsao MS, Tsuboi M, Wakelee HA, Wu YL, Chih-Hsin Yang J, Zhou C, Harpole DH, Kelly KL. Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer. *J Thorac Oncol*. 2024;19(10):1373–1414.
Number of Citations: 14.
Decile 1.
4. Molina-Alejandro M, Perea F, Calvo V, Martinez-Toledo C, Nadal E, Sierra-Rodero B, Casarrubios M, Casal-Rubio J, Martínez-Martí A, Insa A, Massuti B, Viteri S, Barneto Aranda I, Rodríguez-Abreu D, de Castro J, Martínez JM, Cobo M, Wistuba II, Parra ER, Martín-López J, Megías D, Muñoz-Viana R, Garrido F, Aptsiauri N, Ruiz-Cabello F, **PROVENCIO M**, Cruz-Bermúdez A. Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer. *J Immunother Cancer*. 2024;12(10):e009762.
Number of Citations: 1.
Quartile 1.

5. Deutsch JS, Cimino-Mathews A, Thompson E, **PROVENCIO M**, Forde PM, Spicer J et al. Association between pathologic response and survival after neoadjuvant therapy in lung cancer. *Nat Med*. 2024;30(1):218–228.
Number of Citations: 75.
Quartile 1.
6. **PROVENCIO M**, Nadal E, González-Larriba JL, Martínez-Martí A, Bernabé R, Bosch-Barrera J et al. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer. *N Engl J Med*. 2023;389(6):507–518.
Number of Citations: 267.
Decile 1.
7. Zinzani PL, Mayer J, Flowers CR, Bijou F, De Oliveira AC, Song Y, Zhang Q, Merli M, Bouabdallah K, Ganly P, Zhang H, Johnson R, Martín García-Sancho A, **PROVENCIO PULLA M**, Trněný M, Yuen S, Tilly H, Kingsley E, Tumyan G, Assouline SE, Auer R, Ivanova E, Kim P, Huang S, Delarue R, Trotman J. ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma. *J Clin Oncol*. 2023; Nov 20;41(33):5107-5117.
Number of Citations: 51.
Decile 1.
8. **PROVENCIO M**, Ortega AL, Coves-Sarto J, Calvo V, Marsé-Fabregat R, Dómine M et al. Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial. *JAMA Oncol*. 2023;9(3):344–353.
Number of Citations: 29.
Quartile 1.
9. **PROVENCIO M**, Serna-Blasco R, Nadal E, Insa A, García-Campelo MR, Casal Rubio J Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA NSCLC (NADIM phase II trial). *J Clin Oncol*. 2022;40 (25): 2924-2933.
Number of Citations: 258.
Decile 1.
10. Forde PM, Spicer J, Lu S, **PROVENCIO M**, Mitsudomi T, Awad MM et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. *N Engl J Med*. 2022; 386(21): 1973-1985.
Number of Citations: 1824.
Decile 1.
11. Casarrubios M, **PROVENCIO M**, Nadal E, Insa A, Del Rosario García-Campelo M, Lázaro-Quintela M et al. Tumor microenvironment gene expression profiles associated to complete

pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy. *J Immunother Cancer*. 2022;10:e005320.

Number of Citations: 37.

Quartile 1.

12. Torrente M, Sousa PA, Sánchez-Ramos A, Pimentao J, Royuela A, Franco F, Collazo-Lorduy A, Menasalvas E, **PROVENCIO M**. To burn-out or not to burn-out: a cross-sectional study in healthcare professionals in Spain during COVID-19 pandemic. *BMJ Open*. 2021;11(2):e044945.

Number of Citations: 179.

Quartile 1.

13. **PROVENCIO M**, Nadal E, Insa A, García-Campelo MR, Casal-Rubio J, Dómine M et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. *Lancet Oncol*. 2020; 21 (11): 1413-1422.

Number of Citations: 740.

Decile 1.

14. Cruz-Bermúdez A, Laza-Briviesca R, Vicente-Blanco RJ, García-Grande A, Coronado MJ, Laine-Menéndez S, Palacios-Zambrano S, Moreno-Villa MR, Ruiz-Valdepeñas AM, Lendinez C, Romero A, Franco F, Calvo V, Alfaro C, Acosta PM, Salas C, Garcia JM, **PROVENCIO M**. Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1 α in NSCLC which can be overcome by OXPHOS inhibition. *Free Radic Biol Med*. 2019;135:167-181.

Number of Citations: 146.

Quartile 1.

15. Cruz-Bermúdez A, Laza-Briviesca R, Vicente-Blanco RJ, García-Grande A, Coronado MJ, Laine-Menéndez S, Alfaro C, Sanchez JC, Franco F, Calvo V, Romero A, Martin-Acosta P, Salas C, Garcia JM, **PROVENCIO M**. Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF- β signaling. *Free Radic Biol Med*. 2019;130:163-173.

Number of Citations: 122.

Quartile 1.

16. Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, Grohé C, Rodriguez-Abreu D, Abdulla DSY, Bischoff H, Brandts C, Carcereny E, Corral J, Dingemans AC, Pereira E, Fassunke J, Fischer RN, Gardizi M, Heukamp L, Insa A, Kron A, Menon R, Persigehl T, Reck M, Riedel R, Rothschild SI, Scheel AH, Scheffler M, Schmalz P, Smit EF, Limburg M, **PROVENCIO M**, Karachaliou N, Merkelbach-Bruse S, Hellmich M, Nogova L, Büttner R, Rosell R, Wolf J. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. *J Thorac Oncol*. 2019;14(7):1266-127.

Number of Citations: 121.

Decile 1.

17. Reck M, Schenker M, Lee KH, **PROVENCIO M**, Nishio M, Lesniewski-Kmak KJ et al. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. *Eur J Cancer*. 2019;116:137-147.
Number of Citations: 221.
Quartile 1.
18. Jurczak W, Zinzani PL, Gaidano G, Goy A, **PROVENCIO M**, Nagy Z et al. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. *Ann Oncol*. 2018;29(5):1266-1272.
Number of Citations: 138.
Decile 1.
19. Ruiz-Casado A, Martín-Ruiz A, Pérez LM, **PROVENCIO M**, Fiuza-Luces C, Lucia A. Exercise and the Hallmarks of Cancer. *Trends Cancer*. 2017;3(6):423-441.
Number of Citations: 213.
Quartile 1.
20. Paz-Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, **PROVENCIO M** et al. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. *Lancet Oncol*. 2015 Mar;16(3):328-37.
Number of Citations: 152.
Decile 1.

4. Publications from the last 5 years

1. Association of PALB2 Messenger RNA Expression with platinum-docetaxel efficacy in advanced non-small cell lung cancer. Karachaliou N, Bracht JWP, Bruno MF, Drozdowskyj A, Capitan AG, Moran T, Carcereny E, Cobo M, Domine M, Chaib I, Ramirez JL, Camps C, **Provencio M**, Vergnenegre A, Lopez-Vivanco G, Majem M, Massuti B, Rosell R. J Thorac Oncol. 2019, 14 (2): 304-310.
2. Applying Data Science methods and tools to unveil healthcare use of lung cancer patients in a teaching hospital in Spain. Clin Transl Oncol. Cruz-Bermúdez JL, Parejo C, Martínez-Ruiz F, Sánchez-González JC, Ramos Martín-Vegue A, Royuela A, Rodríguez-González A, Menasalvas-Ruiz E, **Provencio M**. 2019 Mar 12. doi: 10.1007/s12094-019-02074-2.
3. Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer. **Provencio M**, Carcereny E, Artal Á. Clin Transl Oncol. 2019 Mar 22.
4. Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer. Majem M, Hernández-Hernández J, Hernando-Trancho F, Rodríguez de Dios N, Sotoca A, Trujillo-Reyes JC, Vollmer I, Delgado-Bolton R, **Provencio M**. Clin Transl Oncol. 2019 Jun 6. doi: 10.1007/s12094-019-02134-7
5. Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group. Rueda A, Calvo V, Casanova M, Rodriguez-Abreu D, Aguiar D, Llanos M, Alvarez R, Martinez-Banaclocha N, Alfaro J, Quero C, Blasco A, de la Cruz Merino L, Herrero J, García-Arroyo FR, **Provencio M**. Leuk Lymphoma. 2018 Dec 5:1-4. doi: 10.1080/10428194.2018.1542147
6. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. Zugazagoitia J, Ramos I, Trigo JM, Palka M, Gómez-Rueda A, Jantus-Lewintre E, Camps C, Isla D, Iranzo P, Ponce-Aix S, García-Campelo R, **Provencio M**, Franco F, Bernabé R, Juan-Vidal O, Felip E, de Castro J, Sanchez-Torres JM, Faul I, Lanman RB, Garrido P, Paz-Ares L. Ann Oncol. 2018 Dec 10. doi: 10.1093/annonc/mdy512

7. Treatment of induction in resectable NSCLC with chemotherapy, followed by surgery and erlotinib. Franco F, **Provencio M**. Ann Transl Med. 2018 Nov;6(Suppl 1):S31. doi: 10.21037/atm.2018.09.38.
8. Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial. Abad, A., Martínez-Balibrea, E., Viéitez, J. M., Alonso-Orduña, V., García Alfonso, P., Manzano, J. L., Massutí, B., Benavides, M., Carrato, A., Zanui, M., Gallego, J., Grávalos, C., Conde, V., **Provencio, M.**, Valladares-Ayerbes, M., Salazar, R., Sastre, J., Montagut, C., Rivera, F., & Aranda, E. (2018). Annals of oncology : official journal of the European Society for Medical Oncology, 29(2), 439–444. <https://doi.org/10.1093/annonc/mdx737>.
9. Long-term follow up of Hodgkin lymphoma. Perez-Callejo, D., Zurutuza, L., Royuela, A., Torrente, M., Núñez, B., Calvo, V., Méndez, M., Franco, F., Brenes, M. A., Sánchez, J. C., & **Provencio, M.** (2018). Oncotarget, 9(14), 11638–11645. <https://doi.org/10.18632/oncotarget.24392>.
10. Alcohol consumption and lung cancer risk in never smokers: a pooled analysis of case-control studies. García Lavandeira, J. A., Ruano-Ravina, A., Kelsey, K. T., Torres-Durán, M., Parente-Lamelas, I., Leiro-Fernández, V., Zapata, M., Abal-Arca, J., Vidal-García, I., Montero-Martínez, C., Amenedo, M., Castro-Añón, O., Golpe-Gómez, A., Guzmán-Taveras, R., Martínez, C., **Provencio, M.**, Mejuto-Martí, M. J., García-García, S., Fernández-Villar, A., Piñeiro, M., ... Barros-Dios, J. M. (2018). European journal of public health, 28(3), 521–527. <https://doi.org/10.1093/eurpub/ckx196>.
11. Hyperprogression as a distinct outcome after immunotherapy. Fuentes-Antrás, J., **Provencio, M.**, & Díaz-Rubio, E. (2018). Cancer treatment reviews, 70, 16–21. <https://doi.org/10.1016/j.ctrv.2018.07.006>.
12. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., Rodríguez-Cid, J., Wilson, J., Sugawara, S., Kato, T., Lee, K. H., Cheng, Y., Novello, S., Halmos, B., Li, X., Lubiniecki, G. M., ... **KEYNOTE-407 Investigators** (2018). The New England journal of medicine, 379(21), 2040–2051. <https://doi.org/10.1056/NEJMoa1810865>.
13. A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study. Martínez, N., Herrera, M., Frías, L., **Provencio, M.**, Pérez-Carrión, R.,

- Díaz, V., Morse, M., & Crespo, M. C. (2019). Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 21(4), 489–498. <https://doi.org/10.1007/s12094-018-1950-0>
14. Nivolumab-associated digital small-vessel vasculitis in a patient with an advanced renal cell carcinoma. Franco F, Méndez M, Gutierrez L, Sanz J, Calvo V, **Provencio M**. Immunotherapy, 2019, 11(5), 379-384.
 15. Transformed Follicular Lymphoma in the Rituximab Era: A Report from the Spanish Lymphoma Oncology Group. Méndez M, Torrente M, Sánchez-Beato M, González-Rincón J, Royuela A, Gómez-Codina J, de la Cruz-Merino L, Rueda A, Llanos M, Quero C, Rodríguez-Abreu D, Gumá J, Monsalvo S, Sabin P, **Provencio M**. Hematol Oncol. 2019 Mar 6
 16. Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma. González-Rincón J, Méndez M, Gómez S, García JF, Martín P, Bellas C, Pedrosa L, Rodríguez-Pinilla SM, Camacho FI, Quero C, Pérez-Callejo D, Rueda A, Llanos M, Gómez-Codina J, Piris MA, Montes-Moreno S, Bárcena C, Rodríguez-Abreu D, Menárguez J, de la Cruz-Merino L, Monsalvo S, Parejo C, Royuela A, Kwee I, Cascione L, Arribas A, Bertoni F, Mollejo M, **Provencio M**, Sánchez-Beato M. PLoS One. 2019 Feb 25;14(2):e0212813.
 17. Genomic analyses of microdissected Hodgkin and Reed-Sternberg cells: mutations in epigenetic regulators and p53 are frequent in refractory classic Hodgkin lymphoma. Mata E, Fernández S, Astudillo A, Fernández R, García-Cosío M, Sánchez-Beato M, **Provencio M**, Estévez M, Montalbán C, Piris MA, García JF. Blood Cancer J. 2019 Mar 11;9(3):34.
 18. Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1 α in NSCLC which can be overcome by OXPHOS inhibition. Alberto Cruz-Bermúdez*, Raquel Laza-Briviesca¹, Ramiro J. Vicente-Blanco¹, Aránzazu García-Grandeb, Maria José Coronadoc, Sara Laine-Menéndez, Sara Palacios-Zambrano, M. Rocío Moreno-Villa, Asunción Martín Ruiz-Valdepeñas, Cristina Lendinez, Atocha Romero, Fernando Franco, Virginia Calvo, Cristina Alfaroa, Paloma Martín Acosta, Clara Salas, José Miguel García, **Mariano Provencio**. Free Radical Biology and medicine 135(2019) 167-181.
 19. Lung cancer and residential radon in never-smokers: A pooling study in the Northwest of Spain. Lorenzo-González M, Ruano-Ravina A, Torres-Durán M, Kelsey KT, **Provencio M**, Parente-Lamelas I, Leiro-Fernández V, Vidal-García I, Castro-Añón O, Martínez C, Golpe-Gómez A, Zapata-Cachafeiro M, Piñeiro-Lamas M, Pérez-Ríos M, Abal-Arca J, Montero-Martínez C, Fernández-Villar A, Barros-Dios JM. Environ Res. 2019 Mar 6;172:713-718.

20. Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. Sequist LV, Gray JE, Harb WA, Lopez-Chavez A, Doebele RC, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, **Provencio M**, Cobo M, Adiwijaya B, Kuesters G, Kamoun WS, Andreas K, Pipas JM, Santillana S, Cho BC, Park K, Shepherd FA. *The Oncologist*. 2019 Apr 11
21. Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase 2 clinical trial. Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, Grohé C, Rodriguez-Abreu D, Abdulla DSY, Bischoff H, Brandts C, Carcereny E, Corral J, Dingemans AC, Pereira E, Fassunke J, Fischer RN, Gardizi M, Heukamp L, Insa A, Kron A, Menon R, Persigehl T, Reck M, Riedel R, Rothschild SI, Scheel AH, Scheffler M, Schmalz P, Smit EF, Limburg M, **Provencio M**, Karachaliou N, Merkelbach-Bruse S, Hellmich M, Nogova L, Büttner R, Rosell R, Wolf J. *J Thorac Oncol*. 2019 Apr 9. pii: S1556-0864(19)30276-X
22. Genetic Variants Associated with Cancer Therapy-Induced Cardiomyopathy. Garcia-Pavia P, Kim Y, Alejandra Restrepo-Cordoba M, Lunde IG, Wakimoto H, Smith AM, Toepfer CN, Getz K, Gorham J, Patel P, Ito K, Willcox JA, Arany Z, Li J, Owens AT, Govind R, Nuñez B, Mazaika E, Bayes-Genis A, Walsh R, Finkelman B, Lupon J, Whiffin N, Serrano I, Midwinter W, Wilk A, Bardaji A, Ingold N, Buchan R, Tayal U, Pascual-Figal DA, de Marvao A, Ahmad M, Garcia-Pinilla JM, Pantazis A, Dominguez F, Baksi AJ, O'Regan DP, Rosen SD, Prasad SK, Lara-Pezzi E, **Provencio M**, Lyon AR, Alonso-Pulpon L, Cook SA, DePalma SR, Barton PJR, Aplenc R, Seidman JG, Ky B, Ware JS, Seidman CE. *Circulation*. 2019 Apr 16. doi: 10.1161/CIRCULATIONAHA.118.037934
23. Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: Safety and efficacy in the phase II checkmate 205 study. Ramchandren R, Domingo-Domenech E, Rueda A, Trney M, Feldman T, Lee H, **Provencio M**, et al. *J Clin Oncol* 37, 21 may, 2019.
24. Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small cell lung cancer. Govindan R, Senan S, Dickgreber N, **Provencio M**, Wu YL, Syrigos K, Parente B, Wilson M, Ziemiecki R, Chouaki N, Hossain A, San Antonio B, Winfree K, Vokes EE. *Curr Med Res Opin*. 2019 May 24:1. doi: 10.1080/03007995.2019.1623185.
25. Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion. Berghoff AS, Bellosillo B, Caux C, de Langen A, Mazieres J, Normanno N, Preusser M, **Provencio M**, Rojo F,

- Wolf J, Zielinski CC. ESMO Open. 2019 Jun 17;4(3):e000498. doi: 10.1136/esmoopen-2019-000498. eCollection 2019. Review.
26. Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF- β signaling. Cruz-Bermúdez, A., Laza-Briviesca, R., Vicente-Blanco, R. J., García-Grande, A., Coronado, M. J., Laine-Menéndez, S., Alfaro, C., Sanchez, J. C., Franco, F., Calvo, V., Romero, A., Martin-Acosta, P., Salas, C., Garcia, J. M., & **Provencio, M.** (2019). Free radical biology & medicine, 130, 163–173. <https://doi.org/10.1016/j.freeradbiomed.2018.10.450>
 27. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. Reck M, Schenker M, Lee KH, **Provencio M**, Nishio M, Lesniewski-Kmak K, Sangha R, Ahmed S, Raimbourg J, Feeney K, Corre R, Franke FA, Richardet E, Penrod JR, Yuan Y, Nathan FE, Bhagavatheeswaran P, DeRosa M, Taylor F, Lawrance R, Brahmer. J. Eur J Cancer. 2019 Jul;116:137-147.
 28. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. Zugazagoitia J, Gómez-Rueda A, Jantus-Lewintre E, Isla D, Camps C, Ramos I, Trigo JM, Bernabé R, Juan-Vidal O, Sanchez-Torres JM, García-Campelo R, **Provencio M**, Felip E, de Castro J, Faull I, Lanman RB, Ponce-Aix S, Paz-Ares L, Garrido P..Lung Cancer. 2019 Aug;134:72-78
 29. ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR790M positive non-small-cell lung cancer. de Marinis F, Wu YL, de Castro G Jr, Chang GC, Chen YM, Cho BC, Freitas HC, Jiang L, Kim SW, Martin C, Metro G, **Provencio M**, Vansteenkiste J, Vicente D, Zhou Q, Miranda MF, Bakker NA, Rigas JR, Cheema PK.. Future Oncol. 2019 Jul 24
 30. Radon exposure: a major cause of lung cancer. Lorenzo-González M, Torres-Durán M, Barbosa-Lorenzo R, **Provencio-Pulla M**, Barros-Dios JM, Ruano-Ravina A. Expert Rev Respir Med. 2019 Jul 24:1-12.
 31. A Next-generation sequencing for tumor mutation quantification using liquid biopsies. **Provencio M**, Pérez-Barrios C, Barquin M, Calvo V, Franco F, Sánchez E, Sánchez R, Marsden D, Cristóbal Sánchez J, Martin Acosta P, Laza-Briviesca R, Cruz-Bermúdez A, Romero Clin Chem Lab Med. 2019 Aug 30. pii: /j/cclm.ahead-of-print/cclm-2019-0745/cclm-2019.
 32. Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study) **Provencio M**, Carcereny E, Rodríguez-Abreu D, López-Castro R, Guirado M, Camps C, Bosch-Barrera J, García-Campelo R, Ortega-Granados AL, González-Larriba JL, Casal-Rubio J, Domine M,

- Massutí B, Sala MÁ, Bernabé R, Oramas J, Del Barco E.. *Transl Lung Cancer Res.* 2019 Aug;8(4):461-475. doi: 10.21037/tlcr.2019.08.05
33. Residential radon, genetic polymorphisms in DNA damage and repair-related. Lorenzo-González M, Ruano-Ravina A, Torres-Durán M, Kelsey KT, **Provencio M**, Parente-Lamelas I, Leiro-Fernández V, Vidal-García I, Castro-Añón O, Martínez C, Golpe-Gómez A, Torres-Español M, Abal-Arca J, Montero-Martínez C, Fernández-Villar A, Barros-Dios JM. *Lung Cancer.* 2019 Sep;135:10-15. doi: 10.1016/j.lungcan.2019.07.003.
 34. Neoadjuvant treatment with tyrosine kinase inhibitors in patients with resectable non-small cell lung cancer. Franco F, **Provencio M**. *J Thorac Dis.* 2019 Oct;11(10):4092-4095. doi: 10.21037/jtd.2019.09.68.
 35. Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study). Isla, D., De Las Peñas, R., Insa, A., Marsé, R., Martínez-Banaclocha, N., Mut, P., Morán, T., Sala, M. Á., Massuti, B., Ortega, A. L., Jurado, J. M., Gómez-Codina, J., Diz, P., Artal, Á., Gutiérrez, V., Vázquez, M. F., Viñolas, N., Maestu, I., Camps, C., Álvarez, R., ... **Provencio, M.** (2019). *Lung cancer* (Amsterdam, Netherlands), 135, 161–168. <https://doi.org/10.1016/j.lungcan.2018.11.041>.
 36. Lung cancer risk and do-it-yourself activities. A neglected risk factor for lung cancer. Lorenzo-González, M., Ruano-Ravina, A., Torres-Durán, M., **Provencio-Pulla, M.**, Kelsey, K., Parente-Lamelas, I., Vidal-García, I., Leiro-Fernández, V., Martínez, C., Hernández, J., Castro-Añón, O., García-García, S., Sales-Fidalgo, P., Abal-Arca, J., Montero-Martínez, C., Pérez-Ríos, M., Fernández-Villar, A., & Barros-Dios, J. M. (2019). *Environmental research*, 179(Pt B), 108812. <https://doi.org/10.1016/j.envres.2019.108812>.
 37. Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer. Karachaliou, N., Bracht, J. W. P., Fernandez Bruno, M., Drozdowskyj, A., Gimenez Capitan, A., Moran, T., Carcereny, E., Cobo, M., Domine, M., Chaib, I., Ramirez, J. L., Camps, C., **Provencio, M.**, Vergnenegre, A., Lopez-Vivanco, G., Majem, M., Massuti, B., & Rosell, R. (2019). *Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer*, 14(2), 304–310. <https://doi.org/10.1016/j.jtho.2018.10.168>.
 38. Applying Data Science methods and tools to unveil healthcare use of lung cancer patients in a teaching hospital in Spain. Cruz-Bermúdez, J. L., Parejo, C., Martínez-Ruíz, F., Sánchez-González, J. C., Ramos Martín-Vegue, A., Royuela, A., Rodríguez-González, A., Menasalvas-

- Ruiz, E., & **Provencio, M.** (2019). Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 21(11), 1472–1481. <https://doi.org/10.1007/s12094-019-02074-2>.
39. Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer. **Provencio, M.**, Carcereny, E., & Artal, Á. (2019). Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 21(11), 1464–1471. <https://doi.org/10.1007/s12094-019-02072-4>.
 40. Radón exposureImmune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion. Berghoff, A. S., Bellosillo, B., Caux, C., de Langen, A., Mazieres, J., Normanno, N., Preusser, M., **Provencio, M.**, Rojo, F., Wolf, J., & Zielinski, C. C. (2019 ESMO open, 4(3), e000498. <https://doi.org/10.1136/esmoopen-2019-000498>
 41. Promotion of Anti-Smoking Strategies as the Most Effective and Efficient Way to Reduce Lung Cancer (and Other Diseases). Ruano-Ravina A, **Provencio-Pulla M**, Fernández-Villar JA Arch Bronconeumol. 2020 Jan 27. pii: S0300-2896(20)30001-6. doi: 10.1016/j.arbres.2019.12.018.
 42. Utilidad clínica de la biopsia líquida para el diagnóstico y seguimiento de los pacientes con CPNM y EML4-ALK. Sánchez-Herrero E, **Provencio M**, Romero A. Adv Lab Med 2020; doi.org/10.1515
 43. Promotion of Anti-Smoking Strategies as the Most Effective and Efficient Way to Reduce Lung Cancer (and Other Diseases). Ruano-Ravina A, **Provencio-Pulla M**, Fernández-Villar JA. Arch Bronconeumol. 2020 May;56(5):339. doi: 10.1016/j.arbres.2019.12.018. Epub 2020.
 44. ¿Puede data science ayudarnos a mejorar el pronóstico y tratamiento del paciente oncológico?. Menasalvas, E., Rodríguez-González A., Torenté, M., **Provencio, M.** 2020. Comunicación y Hombre. UNIV FRANCISCO VITORIA Vol 16, PP.151-166. ISBN/ISSN: 1885-365X;1885-9542
 45. Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer. Majem, M., Hernández-Hernández, J., Hernando-Trancho, F., Rodríguez de Dios, N., Sotoca, A., Trujillo-Reyes, J. C., Vollmer, I., Delgado-Bolton, R., & **Provencio, M.** (2020). Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 22(1), 21–36. <https://doi.org/10.1007/s12094-019-02134-7>

46. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, **Provencio M**, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y. *J Thorac Oncol*. 2020 Jan 28. pii: S1556-0864(20)30026-5
47. Benefits of exercise and immunotherapy in a murine model of human non-small-cell lung carcinoma. Martín-Ruiz A, Fiuza-Luces C, Rincón-Castanedo C, Fernández-Moreno D, Gálvez BG, Martínez-Martínez E, Martín-Acosta P, Coronado MJ, Franco-Luzón L, González-Murillo Á, Ramírez M, **Provencio M**, Lucia A. *Exerc Immunol Rev*. 2020;26:100-115.
48. Development of a Multicriteria Decision Analysis Framework for Evaluating and Positioning Oncologic Treatments in Clinical Practice. Camps C, Badia X, García-Campelo R, García-Foncillas J, López R, Massuti B, **Provencio M**, Salazar R, Virizuela J, Guillem V. *JCO Oncol Pract*. 2020 Mar;16(3):e298-e305.
49. Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection: The Phase 2 DURVAST Study. Gonzalez-Cao M, Morán T, Dalmau J, Garcia-Corbacho J, Bracht JWP, Bernabe R, Juan O, de Castro J, Blanco R, Drozdowskyj A, Argilaguet J, Meyerhans A, Blanco J, Prado JG, Carrillo J, Clotet B, Massuti B, **Provencio M**, Molina-Vila MA, Mayo de Las Casa C, Garzon M, Cao P, Huang CY, Martinez-Picado J, Rosell R. *JAMA Oncol*. 2020 Apr 9. doi: 10.1001/jamaoncol.2020.0465
50. How we treat patients with lung cancer during the SARS-CoV-2 pandemic. Provencio M, Ruano-Raviña A. *ESMO Open*. 2020 May;4(Suppl 2). pii: e000785. doi: 10.1136/esmoopen-2020-000785
51. A Next-generation sequencing to dynamically detect mechanisms of resistance to ALK inhibitors in ALK-positive NSCLC patients: a case report. Sánchez-Herrero E, Blanco Clemente M, Calvo V, **Provencio M**, Romero *Transl Lung Cancer Res*. 2020 Apr;9(2):366-372. doi: 10.21037/tlcr.2020.02.07.
52. Effects of anti-PD-1 immunotherapy on tumor regression: insights from a patient-derived xenograft model. Martín-Ruiz A, Fiuza-Luces C, Martínez-Martínez E, Arias CF, Gutiérrez L, Ramírez M, Martín-Acosta P, Coronado MJ, Lucia A, **Provencio M** *Sci Rep*. 2020 Apr

27;10(1):7078. doi: 10.1038/s41598-020-63796-w.

53. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. **Provencio M**, Nadal E, Insa A, García-Campelo MR, Casal-Rubio J, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Pereira E, Royuela A, Casarrubios M, Salas Antón C, Parra ER, Wistuba I, Calvo V, Laza-Briviesca R, Romero A, Massuti B, Cruz-Bermúdez A. *Lancet Oncol*. 2020 Nov;21(11):1413-1422. doi: 10.1016/S1470-2045(20)30453-8. Epub 2020 Sep 24.
54. Next-generation sequencing for tumor mutation quantification using liquid biopsies. **Provencio M**, Pérez-Barrios C, Barquin M, Calvo V, Franco F, Sánchez E, Sánchez R, Marsden D, Cristóbal Sánchez J, Martin Acosta P, Laza-Briviesca R, Cruz-Bermúdez A, Romero A. *Clin Chem Lab Med*. 2020 Jan 28;58(2):306-313. doi: 10.1515/cclm-2019-0745.
55. ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib. Romero A, Serna-Blasco R, Alfaro C, Sánchez-Herrero E, Barquín M, Turpin MC, Chico S, Sanz-Moreno S, Rodríguez-Festa A, Laza-Briviesca R, Cruz-Bermudez A, Calvo V, Royuela A, **Provencio M**. *Transl Lung Cancer Res*. 2020 Jun;9(3):532-540. doi: 10.21037/tlcr.2020.04.01.
56. A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial. Peters S, Danson S, Hasan B, Dafni U, Reinmuth N, Majem M, Tournoy KG, Mark MT, Pless M, Cobo M, Rodríguez-Abreu D, Falchero L, Moran T, Ortega Granados AL, Monnet I, Mohorcic K, Sureda BM, Betticher D, Demedts I, Macias JA, Cuffe S, Luciani A, Sanchez JG, Curioni-Fontecedro A, Gautschi O, Price G, Coate L, von Moos R, Zielinski C, **Provencio M**, Menis J, Ruepp B, Pochesci A, Roschitzki-Voser H, Besse B, Rabaglio M, O'Brien MER, Stahel RA. *J Thorac Oncol*. 2020 Oct;15(10):1647-1656. doi: 10.1016/j.jtho.2020.06.011. Epub 2020 Jun 18
57. Reconstructing the patient's natural history from electronic health records. Najafabadipour M, Zanin M, Rodríguez-González A, Torrente M, Nuñez García B, Cruz Bermudez JL, **Provencio M**, Menasalvas E. *Artif Intell Med*. 2020 May;105:101860. doi: 10.1016/j.artmed.2020.101860. Epub 2020 May 3.

58. Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group. Remon J, Nadal E, Dómine M, Ruffinelli J, García Y, Pardo JC, López R, Cilleruelo A, García-Campelo R, Martín P, Juan O, González-Larriba JL, **Provencio M**, Olmedo E, Ponce S, Cumplido D, Barenys C, Majem M, Massutti B, Rodriguez-Abreu D, Porta R, Sala MA, Martinez-Kareaga M, Lianes P, Reguart N. *Lung Cancer*. 2020 Sep;147:83-90. doi: 10.1016/j.lungcan.2020.06.034. Epub 2020 Jul 3. PMID: 32682189
59. Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial. Romero A, Jantus-Lewintre E, García-Peláez B, Royuela A, Insa A, Cruz P, Collazo A, Pérez Altozano J, Vidal OJ, Diz P, Cobo M, Hernández B, Vázquez Estevez S, Benítez G, Guirado M, Majem M, Bernabé R, Ortega AL, Blasco A, Bosch-Barrera J, Jurado JM, García González J, Viteri S, Garcia Giron C, Massutí B, Lopez Martín A, Rodriguez-Festa A, Calabuig-Fariñas S, Molina-Vila MÁ, **Provencio M**. *Mol Oncol*. 2020 Oct 26. doi: 10.1002/1878-0261.12832. Online ahead of print.
60. How do we Classify a Central Tumor? Results of a Multidisciplinary Survey from the SEPAR Thoracic Oncology Area. Martínez-Palau M, Trujillo-Reyes JC, Jaen À, Call S, Martínez-Hernández NJ, **Provencio M**, Vollmer I, Rami-Porta R, Sanz-Santos J. *Arch Bronconeumol*. 2020 Aug 20:S0300-2896(20)30210-6. doi: 10.1016/j.arbres.2020.06.009. Online ahead of print.
61. Lung cancer risk and residential astris: A pooling of case-control studies in northwestern Spain. Lorenzo-Gonzalez M, Ruano-Ravina A, Torres-Duran M, Kelsey KT, **Provencio M**, Parente-Lamelas I, Piñeiro-Lamas M, Varela-Lema L, Perez-Rios M, Fernandez-Villar A, Barros-Dios JM. *Environ Res*. 2020 Oct;189:109968. doi: 10.1016/j.envres.2020.109968. Epub 2020 Jul 25.
62. OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors. Gutierrez, M., Moreno, V., Heinhuis, K. M., Olszanski, A. J., Spreafico, A., Ong, M., Chu, Q., Carvajal, R. D., Trigo, J., Ochoa de Olza, M., **Provencio, M.**, De Vos, F. Y., De Braud, F., Leong, S., Lathers, D., Wang, R., Ravindran, P., Feng, Y., Aanur, P., & Melero, I. (2021). *Clinical cancer research: an official journal of the American Association for Cancer Research*, 27(2), 460–472. <https://doi.org/10.1158/1078-0432.CCR-20-1830>
63. Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation. Barquín M, Calvo V, García-García F, Nuñez B, Sánchez-Herrero E, Serna-Blasco R, Auglyté M, Carcereny E, Rodriguez-Abreu D, López Castro R,

- Guirado M, Camps C, Bosch-Barrera J, Massuti B, Ortega AL, Del Barco E, Gonzalez-Larriba JL, Aguiar D, García-Campelo R, Dómine M, Agraso S, Sala MA, Oramas J, Bernabé R, Blanco R, Parejo C, Cruz A, Menasalvas E, Royuela A, Romero A, **Provencio M**. *Cancer Epidemiol*. 2020 Aug;67:101737. doi: 10.1016/j.canep.2020.101737. Epub 2020 May 22. PMID: 32450544
64. Lung cancer symptoms at diagnosis: results of a nationwide registry study. A Ruano, **M Provencio**, V Calvo, et al. *ESMO Open* 2020; 5e001021. doi: 10.1136/esmoopen-2020-001021.
 65. Immunotherapy moves to the Early-stage setting in Non-small cell lung cancer: Emerging evidence and the role of biomarkers. X Mielgo, V Calvo, J Luna, J Remón, M Martín, P Berraondo, J R Jarabo, O Higuera, E Conde, J de Castro, **M Provencio**, F Hernando-Trancho, F López-Rios, F Couñago. *Cancers* 2020; 12, 3459. Doi: 10.3390/cancers12113459.
 66. Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer. Liang W, Cai K, Chen C, Chen H, Chen Q, Fu J, Hu J, Jiang T, Jiao W, Li S, Liu C, Liu D, Liu W, Liu Y, Ma H, Pan X, Qiao G, Tian H, Wei L, Zhang Y, Zhao S, Zhao X, Zhou C, Zhu Y, Zhong R, Li F, Rosell R, **Provencio M**, et al ... He, J. (2020). *Translational lung cancer research*, 9(6), 2696–2715. <https://doi.org/10.21037/tlcr-2020-63>
 67. Integrating speculation detection and Deep learning to extract lung cancer diagnosis from clinical notes. Solarte O, Torrente M, **Provencio M**, Rodríguez-González A, Menasalvas E. *Appl Sci* 2021, 1, 0. <https://dx.doi.org/10.3390/app1010000>
 68. Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review. A Ortega-Franco, V Calvo, F Franco, **M Provencio**, R Califano. *Transl Lung Cancer Res* 2020; 9(6): 2656-267 <http://dx.doi.org/10.21037/tlcr-20-546>.
 69. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. Shaw, A. T., Bauer, T. M., de Marinis, F., Felip, E., Goto, Y., Liu, G., Mazieres, J., Kim, D. W., Mok, T., Polli, A., Thurm, H., Calella, A. M., Peltz, G., Solomon, B. J., & **CROWN Trial Investigators** (2020). *The New England journal of medicine*, 383(21), 2018–2029. <https://doi.org/10.1056/NEJMoa2027187>.
 70. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. Wu, Y. L., Tsuboi, M., He, J., John, T., Grohe, C., Majem, M., Goldman, J. W., Laktionov, K., Kim, S. W., Kato, T., Vu, H. V., Lu, S., Lee, K. Y., Akewanlop, C., Yu, C. J., de Marinis, F., Bonanno, L., Domine, M., Shepherd, F. A., Zeng, L., ... **ADAURA Investigators** (2020). *The New England journal of medicine*, 383(18), 1711–1723. <https://doi.org/10.1056/NEJMoa2027071>.
 71. Polymorphisms in the BER and NER pathways and their influence on survival and toxicity in

- never-smokers with lung cancer. Casal-Mouriño, A., Ruano-Ravina, A., Torres-Durán, M., Parente-Lamelas, I., **Provencio-Pulla, M.**, Castro-Añón, O., Vidal-García, I., Abal-Arca, J., Piñeiro-Lamas, M., Fernández-Villar, A., Valdés-Cuadrado, L., Barros-Dios, J. M., & Pérez-Ríos, M. (2020). Scientific reports, 10(1), 21147. <https://doi.org/10.1038/s41598-020-78051-5>.
72. Effect of intravenous lidocaine on ischemia-reperfusion injury in DIEP microsurgical breast reconstruction. A prospective double-blind randomized controlled clinical trial. Del Rio, M., Lopez-Cabrera, P., Malagón-López, P., Del Caño-Aldonza, M. C., Castello, J. R., & **Provencio, M.** (2021). Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 74(4), 809–818. <https://doi.org/10.1016/j.bjps.2020.10.018>.
 73. ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort. Vicente-Baz, D., Paredes, A., Morán, T., Massuti, B., Reguart, N., Álvarez, R., Insa, A., Juan-Vidal, O., Artal, Á., Esteban, E., García-Campelo, R., Ortega-Granados, A. L., Diz, P., González-Larriba, J. L., Terrasa, J., de Las Peñas, R., Rodríguez-Abreu, D., Callejo, Á., Márquez, G., & **Provencio, M.** (2020). Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia, 53(3), 140–148. <https://doi.org/10.1016/j.patol.2019.11.002>.
 74. Development of a Multicriteria Decision Analysis Framework for Evaluating and Positioning Oncologic Treatments in Clinical Practice. Camps, C., Badia, X., García-Campelo, R., García-Foncillas, J., López, R., Massuti, B., **Provencio, M.**, Salazar, R., Virizuela, J., & Guillem, V. (2020). JCO oncology practice, 16(3), e298–e305. <https://doi.org/10.1200/JOP.19.00487>.
 75. Lung cancer survival in never-smokers and exposure to residential radon: Results of the LCRINS study. Casal-Mouriño, A., Ruano-Ravina, A., Torres-Durán, M., Parente-Lamelas, I., **Provencio-Pulla, M.**, Castro-Añón, O., Vidal-García, I., Pena-Álvarez, C., Abal-Arca, J., Piñeiro-Lamas, M., Fuente-Merino, I., Fernández-Villar, A., Abdulkader, I., Valdés-Cuadrado, L., Barros-Dios, J. M., & Pérez-Ríos, M. (2020). Cancer letters, 487, 21–26. <https://doi.org/10.1016/j.canlet.2020.05.022>.
 76. Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer. Liang W, Cai K, Chen C, Chen H, Chen Q, Fu J, Hu J, Jiang T, Jiao W, Li S, Liu C, Liu D, Liu W, Liu Y, Ma H, Pan X, Qiao G, Tian H, Wei L, Zhang Y, Zhao S, Zhao X, Zhou C, Zhu Y, Zhong R, Li F, Rosell R, **Provencio M**, Massarelli E, Antonoff MB, Hida T, de Perrot M, Lin SH, Di Maio M, Rossi A, De

- Ruysscher D, Ramirez RA, Dempke WCM, Camidge DR, Guibert N, Califano R, Wang Q, Ren S, Zhou C, He J. *Transl Lung Cancer Res*. 2020 Dec;9(6):2696-2715. doi: 10.21037/tlcr-2020-63. PMID: 33489828; PMCID: PMC7815365.
77. Overall survival for early and locally advanced non-small-cell lung cancer from one institution: 2000-2017. González M, Calvo V, Redondo I, **Provencio M**. *Clin Transl Oncol*. 2021 Feb 2. doi: 10.1007/s12094-020-02521-5.
 78. Future care for long-term cancer survivors: towards a new model. Provencio M, Romero N, Tabernero J, et al. *Clin Trans Oncol* doi.org/10.1007/st12094-021-02696-5.
 79. Residential Radon and Small Cell Lung Cancer. Final Results of the Small Cell Study. Rodríguez-Martínez Á, Ruano-Ravina A, Torres-Durán M, **Provencio M**, Parente-Lamelas I, Vidal-García I, Martínez C, Hernández-Hernández J, Abdulkader-Nallib I, Castro-Añón O, Varela-Lema L, Piñeiro-Lamas M, Fidalgo PS, Fernández-Villar A, Barros-Dios J, Pérez-Ríos M. *Arch Bronconeumol*. 2021 Feb 13:S0300-2896(21)00052-1. doi: 10.1016/j.arbres.2021.01.027. Online ahead of print.
 80. Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer. Analysis of survival and value of ctDNA for patient selection. **Provencio M**, Majem M, Guirado M, et al. *Lung Cancer* 2021; 153: 25-34.
 81. Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma. Pedrosa L, Fernández-Miranda I, Pérez-Callejo D, Quero C, Rodríguez M, Martín-Acosta P, Gómez S, González-Rincón J, Santos A, Tarin C, García JF, García-Arroyo FR, Rueda A, Camacho FI, García-Cosío M, Heredero A, Llanos M, Mollejo M, Piris-Villaespesa M, Gómez-Codina J, Yanguas-Casás N, Sánchez A, Piris MA, **Provencio M**, Sánchez-Beato M. *Sci Rep*. 2021 Jan 21;11(1):1886. doi: 10.1038/s41598-020-80376-0.
 82. Functional Signatures in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Sex-Based Differences in Transcriptomic Studies. Pérez-Díez I, Hidalgo MR, Malmierca-Merlo P, Andreu Z, Romera-Giner S, Farràs R, de la Iglesia-Vayá M, **Provencio M**, Romero A, García-García F. *Cancers (Basel)*. 2021 Jan 5;13(1):143. Doi:10.3390/cancers13010143.
 83. Prognostic factors in potentially resectable stage III non-small cell lung cancer receiving neoadjuvant treatment-a narrative review. V Calvo, C Aliaga, C Carracedo, **M Provencio**. *Trans Lung Cancer Res* 2021; 10(1): 581-589. <http://dx.doi.org/10.21037/tlcr-20-515>

84. COVID-19 in Melanoma Patients: Results of the Spanish Melanoma Group Registry, GRAVID study. Gonzalez-Cao M, Carrera C, Rodriguez Moreno JF, Rodríguez-Jiménez P, Antónanzas Basa M, Feltes Ochoa R, Puertolas T, Muñoz E, Manzano JL, Marquez-Rodas I, Martín-Liberal J, Soria A, Criado PL, García Castaño A, Boada A, Ayala de Miguel P, Puig S, Crespo G, Luna Fra P, Aguayo Zamora C, Feito Rodríguez M, Valles L, Drozdowskyj A, Seral CM, Gardeazabal J, Villalobos L, Rosell R, Fernandez-Morales LA, Rodrigo A, Viteri S, **Provencio M**, Berrocal A; Spanish Melanoma Group (GEM). *J Am Acad Dermatol*. 2021 Feb 10:S0190-9622(21)00337-6. doi: 10.1016/j.jaad.2021.02.013.
85. To burn-out or not to burn-out: a cross-sectional study in healthcare professionals in Spain during COVID-19 pandemic. Torrente M, Sousa P, Sánchez-Ramos A, Pimentao J, Royuela A, Franco F, Collazo-Lorduy A, Menasalvas E, **Provencio M**. *BMJ Open* 2021; 11:e044945.
86. Osimertinib in advanced EGFR T790M mutation-positive non-small cell lung cancer patients treated within the special use medication program in Spain: OSIREX-Spanish Lung Cancer Group. **Provencio M**, Terrasa J, Garrido P, et al. *BMC Cancer* 2021; 21:230. Doi: 10.1186/sr12885-021-07922-5.
87. Small-cell lung cancer in never-smokers. Torres-Duran M, Curiel MT, Ruano A, **Provencio M**, et al. *ESMO Open* 2021, Feb 25; 6 (2): 100059.
88. Outcomes of surgical resection after neoadjuvant chemoimmunotherapy in locally advanced stage IIIA non-small-cell lung cancer. Romero Román A, Campo-Cañaveral de la Cruz JL, Macía I, Escobar Campuzano I, Figueroa Almánzar S, Delgado Roel M, Gálvez Muñoz C, García Fontán EM, Muguruza Trueba I, Romero Vielva L, Cano Garcia JR, Martínez Téllez E, Partida González C, Jiménez López MF, Jiménez Maestre U, Mongil Poce R, Sánchez Lorente D, Álvarez Kindelán A, **Provencio Pulla M**. *Eur J Cardiothorac Surg*. 2021 Jul 14;60(1):81-88. doi: 10.1093/ejcts/ezab007. PMID: 33661301.
89. ctDNA from body fluids is an adequate source for EGFR biomarker testing in advanced lung adenocarcinoma. Pérez-Barrios C, Sánchez-Herrero E, Garcia-Simón N, Barquín M, Clemente MB, **Provencio M**, Romero A. *Clin Chem Lab Med*. 2021 Mar 10. doi: 10.1515/cclm-2020-1465.
90. Lung cancer patients with COVID-19 in Spain: GRAVID Study. **Provencio M**, Mazarico JM, Calles A, et al. *Lung Cancer* 2021.

91. Cancer and SARS-Co-2 infection: A third-level hospital experience. Calvo V, Fernández-Cruz A, B Núñez, Blanco M, Morito A, Martínez M, Traseira C, Garitaonandia Y, Aguado R, Royuela A, Ramos A, Franco F, **Provencio M**. *Clinical Epidemiology* 2021; 13: 317-324.
92. Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer in vitro and in vivo. Li T, Qian Y, Zhang Ch, Uchino J, **Provencio M**, Wang Y, Shi X, Zhang Y, Zhang X. *Trans Lung Cancer Res* 2021; 10 (4): 1873-1888.
93. The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy. Cruz-Bermúdez A, Laza-Briviesca R, Casarrubios M, Sierra-Rodero B, **Provencio M**. *Biomedicines*. 2021 Mar 31;9(4):361. doi: 10.3390/biomedicines9040361.
94. Residential radon and lung cancer characteristics at diagnosis. Torres-Durán M, Casal-Mouriño A, Ruano-Ravina A, **Provencio M**, Parente-Lamelas I, Hernández-Hernández J, Vidal-García I, Varela-Lema L, Valdés Cuadrado L, Fernández-Villar A, Barros-Dios J, Pérez-Ríos M. *Int J Radiat Biol*. 2021 Apr 15:1-6. doi: 10.1080/09553002.2021.1913527. Online ahead of print.PMID: 33856283
95. Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel). Franco F, Guirado M, Martínez-Banaclocha N, Gumà J, Lavernia J, Gómez-Codina J, Rodríguez-Abreu D, Martínez F, Barrajón E, Méndez M, Calvo V, **Provencio M**. *Curr Oncol*. 2021 Mar 16;28(2):1249-1255. doi: 10.3390/curroncol28020118.
96. Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry. Franco F, Carcereny E, Guirado M, Ortega AL, López-Castro R, Rodríguez-Abreu D, García-Campelo R, Del Barco E, Juan O, Aparisi F, González-Larriba JL, Domine M, Trigo JM, Cobo M, Cerezo S, Calzas J, Massutí B, Bosch-Barrera J, García Coves P, Domènech M, **Provencio M**. *PLoS One*. 2021 Jun 2;16(6):e0251761. doi: 10.1371/journal.pone.0251761
97. Prospective exploratory analysis of angiogenic circulating biomarkers in advanced NSCLC patients treated with bevacizumab plus chemotherapy. The ANGIOMET study. Jantus-Lewintre E, Massuti B, González-Larriba JL, Rodríguez-Abreu D, Juan O, Blasco A, Domine M, **Provencio M**, et al. *Frontiers in Oncology*, 2021.doi: 10.3389/fonc.2021.695038.
98. Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from

- the R2-GDP-GOTEL trial. Jiménez-Cortegana C, Palazón-Carrión N, Martín García-Sancho A, Nogales-Fernández E, Carnicero-González F, Ríos-Herranz E, de la Cruz-Vicente F, Rodríguez-García G, Fernández-Álvarez R, Rueda Domínguez A, Casanova-Espinosa M, Martínez-Banaclocha N, Gumà-Padrò J, Gómez-Codina J, Labrador J, Salar-Silvestre A, Rodríguez-Abreu D, Galvez-Carvajal L, **Provencio M**, Sánchez-Beato M, Guirado-Risueño M, Espejo-García P, Lejeune M, Álvaro T, Sánchez-Margalet V, de la Cruz-Merino L; Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA); Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA); Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA). *J Immunother Cancer*. 2021 Jun;9(6):e002323. doi: 10.1136/jitc-2020-002323.
99. Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review. Zhang Z, Yang S, Ma Y, Zhou H, Wu X, Han J, Hou J, Hao L, Spicer JD, Koh YW, **Provencio M**, Reguart N, Mitsudomi T, Wang Q. *Transl Lung Cancer Res*. 2021 Jun;10(6):2715-2732. doi: 10.21037/tlcr-21-423.
 100. Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer. Chen Y, Yan B, Xu F, Hui Z, Zhao G, Liu J, Zhang H, Zeng Z, Zhang R, **Provencio M**, Ren X, You J. *Transl Lung Cancer Res*. 2021 May;10(5):2193-2204. doi: 10.21037/tlcr-21-329.
 101. Evaluation of the reporting quality of clinical practice guidelines on lung cancer using the RIGHT checklist. Yang Y, Lu J, Ma Y, Xi C, Kang J, Zhang Q, Jia X, Liu K, Du S, Kocher F, Seeber A, Gridelli C, **Provencio M**, Seki N, Tomita Y, Zhang X. *Transl Lung Cancer Res*. 2021 Jun;10(6):2588-2602. doi: 10.21037/tlcr-21-405.
 102. Spanish Lung Cancer Group SCAT trial: surgical audit to lymph node assessment based on IASLC recommendations. Jarabo Sarceda JR, Bolufer Nadal S, Mongil Poce R, López de Castro P, Moreno Balsalobre R, Peñalver Cuesta JC, Embún Flor R, Pac Ferrer J, Algar Algar FJ, Gámez García AP, Jiménez MF, Sales-Badía JG, Pereira E, Massuti B, **Provencio M**, Hernando Tranco F. *Transl Lung Cancer Res*. 2021 Apr;10(4):1761-1772. doi: 10.21037/tlcr-20-1055.
 103. Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment. **Provencio M**, Serna-Blasco R, Franco F, Calvo V, Royuela A, Auglyté M, Sánchez-Hernández A, de Julián Campayo M, García-Girón C, Dómine M, Blasco A, Sánchez JM, Oramas J, Bosch-Barrera J, Sala MÁ, Sereno M, Ortega AL, Chara L, Hernández B,

- Padilla A, Coves J, Blanco R, Balsalobre J, Mielgo X, Bueno C, Jantus-Lewintre E, Molina-Vila MÁ, Romero A. *Eur J Cancer*. 2021 May;149:61-72. doi: 10.1016/j.ejca.2021.02.031. Epub 2021 Apr 5.
104. NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment. Sánchez-Herrero E, Serna-Blasco R, Ivanchuk V, García-Campelo R, Dómine Gómez M, Sánchez JM, Massutí B, Reguart N, Camps C, Sanz-Moreno S, Calabuig-Fariñas S, Jantus-Lewintre E, Arnal M, Fernández-Orth D, Calvo V, González-Rumayor V, **Provencio M**, Romero A. *Mol Oncol*. 2021 May 31. doi: 10.1002/1878-0261.13033.
 105. Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. Laza-Briviesca R, Cruz-Bermúdez A, Nadal E, Insa A, García-Campelo MDR, Huidobro G, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Massuti B, Casarrubios M, Sierra-Rodero B, Tarín C, García-Grande A, Haymaker C, Wistuba II, Romero A, Franco F, **Provencio M**. *Clin Transl Med*. 2021 Jul;11(7):e491. doi: 10.1002/ctm2.491.
 106. Use of Liquid Biopsy in the Care of Patients with Non-Small Cell Lung Cancer. Romero A, Serna-Blasco R, Calvo V, **Provencio M**. *Curr Treat Options Oncol*. 2021 Aug 23;22(10):86. doi: 10.1007/s11864-021-00882-9.
 107. Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges. Mielgo-Rubio X, Martín M, Remon J, Higuera O, Calvo V, Jarabo JR, Conde E, Luna J, **Provencio M**, De Castro J, López-Ríos F, Hernando-Trancho F, Couñago F *Future Oncol*. 2021 Aug 2. doi: 10.2217/fon-2020-1255
 108. Pre-treatment tissue TCR repertoire evenness is associated with complete pathological response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy. Casarrubios M, Cruz-Bermúdez A, Nadal E, Insa A, Garcia-Campelo R, Lázaro M, Dómine M, Majem M, Rodríguez-Abreu D, Martinez-Marti A, de Castro-Carpeño J, Cobo M, López-Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Massuti B, Barquin M, Laza-Briviesca R, Sierra-Rodero B, Parra ER, Sanchez-Espiridion B, Rocha P, Kadara H, Wistuba II, Romero A, Calvo V, **Provencio M**. *Clin Cancer Res*. 2021 Aug 10:clincanres.1200.2021. doi: 10.1158/1078-0432.CCR-21-1200.

109. Evaluation of the reporting quality of clinical practice guidelines on lung cancer using the RIGHT checklist. Yang Y, Lu J, Ma Y, Xi C, Kang J, Zhang Q, Jia X, Liu K, Du S, Kocher F, Seeber A, Gridelli C, **Provencio M**, Seki N, Tomita Y, Zhang X. Transl Lung Cancer Res. 2021 Jun;10(6):2588-2602. doi: 10.21037/tlcr-21-405.
110. Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data. Gutiérrez L, Royuela A, Carcereny E, López-Castro R, Rodríguez-Abreu D, Massuti B, González-Larriba JL, García-Campelo R, Bosch-Barrera J, Guirado M, Camps C, Dómine M, Bernabé R, Casal J, Oramas J, Ortega AL, Sala MA, Padilla A, Aguiar D, Juan-Vidal O, Blanco R, Del Barco E, Martínez-Banaclocha N, Benítez G, de Vega B, Hernández A, Saigi M, Franco F, **Provencio M**. BMC Cancer. 2021 Aug 31;21(1):977. doi: 10.1186/s12885-021-08713-8.
111. Consolidation nivolumab and ipilimumab versus observation in limited-disease small cell lung cancer after chemo-radiotherapy - Results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. Peters S, Pujol JL, Dafni U, Dómine M, Popat S, Reck M, Andrade J, Becker A, Moro-Sibilot D, Curioni-Fontecedro A, Molinier O, Nackaerts K, Mollá AI, Gervais R, Vivanco GL, Madelaine J, Mazieres J, Faehling M, Griesinger F, Majem M, Larriba JLG, **Pulla MP**, Vervita K, Roschitzki-Voser H, Ruepp B, Mitchell P, Stahel RA, Le Pechoux C, De Ruyscher D, ETOP/IFCT 4-12 STIMULI Collaborators.; Ann Oncol. 2021 Sep 22:S0923-7534(21)04490-2. Doi 10.1016/j.annonc.2021.09.011. Online ahead of print.
112. Lung Cancer Screening Quality Criteria: A Population Perspective. Candal-Pedreira C, Ruano-Ravina A, **Provencio M**, Fernández-Villar A, Pérez-Ríos M. Chest. 2021 Oct;160(4):e329-e331. doi: 10.1016/j.chest.2021.05.006.
113. Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer. Qiu B, Cai K, Chen C, Chen J, Chen KN, Chen QX, Cheng C, Dai TY, Fan J, Fan Z, Hu J, Hu WD, Huang YC, Jiang GN, Jiang J, Jiang T, Jiao WJ, Li HC, Li Q, Liao YD, Liu HX, Liu JF, Liu L, Liu Y, Long H, Luo QQ, Ma HT, Mao NQ, Pan XJ, Tan F, Tan LJ, Tian H, Wang D, Wang WX, Wei L, Wu N, Wu QC, Xiang J, Xu SD, Yang L, Zhang H, Zhang L, Zhang P, Zhang Y, Zhang Z, Zhu K, Zhu Y, Um SW, Oh IJ, Tomita Y, Watanabe S, Nakada T, Seki N, Hida T, Sasada S, Uchino J, Sugimura H, Dermime S, Cappuzzo F, Rizzo S, Cho WC, Crucitti P, Longo F, Lee KY, De Ruyscher D, Vanneste BGL, Furqan M, Sieren JC, Yendamuri S, Merrell KW, Molina JR, Metro G, Califano R, Bongiolatti S, **Provencio M**, Hofman P, Gao S, He J. Transl Lung Cancer Res. 2021 Sep;10(9):3713-3736. doi: 10.21037/tlcr-21-634. PMID: 34733623; PMCID: PMC8512472.

114. Thymic tumors: a single center surgical experience and literature review on the current diagnosis and management of thymic malignancies. Minervini F, Boschetti L, Gregor M, **Provencio M**, et al. *Gland Surg* 2021, doi: 10.21037.
115. Monitoring therapeutic response and resistance with liquid biopsy. Clavo V, Romero A, **Provencio M**. *Precis Cancer Med* 2021, 4:15.
116. Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung Cancer patients who received immunotherapy-based treatments. Shi Y, Liu X, Zhang D, et al. *Transl Lung Cancer Res* 2021; 10 (12): 4477-4493.
117. Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges. Mielgo-Rubio X, Martín M, Remon J, Higuera O, Calvo V, Jarabo JR, Conde E, Luna J, **Provencio M**, De Castro J, López-Ríos F, Hernando-Trancho F, Couñago F. *Future Oncol.* 2021 Oct;17(30):4011-4025. doi: 10.2217/fon-2020-1255. Epub 2021 Aug 2.
118. Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data. Calvo V, Fernández MA, Collazo-Lorduy A, Franco F, Núñez B, **Provencio M**. *Lung Cancer Manag.* 2021 Jul 2;10(4):LMT51. doi: 10.2217/lmt-2021-0003. eCollection 2021 Dec.
119. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. Paz-Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, Urban L, Caro RB, Park K, Sakai H, Ohe Y, Nishio M, Audigier-Valette C, Burgers JA, Pluzanski A, Sangha R, Gallardo C, Takeda M, Linardou H, Lupinacci L, Lee KH, Caserta C, **Provencio M**, Carcereny E, Otterson GA, Schenker M, Zurawski B, Alexandru A, Vergnenegre A, Raimbourg J, Feeney K, Kim SW, Borghaei H, O'Byrne KJ, Hellmann MD, Memaj A, Nathan FE, Bushong J, Tran P, Brahmer JR, Reck M. *J Thorac Oncol.* 2022 Feb;17(2):289-308. doi: 10.1016/j.jtho.2021.09.010. Epub 2021 Oct 12
120. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. Soo RA, Han JY, Dafni U, Cho BC, Yeo CM, Nadal E, Carcereny E, de Castro J, Sala MA, Bernabé R, Coate L, **Provencio Pulla M**, Garcia Campelo R, Cuffe S, Hashemi SMS, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres JM, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel RA, Peters S; ETOP 10-16 BOOSTER

- Collaborators. *Ann Oncol.* 2022 Feb;33(2):181-192. doi: 10.1016/j.annonc.2021.11.010. Epub 2021 Nov 26.
121. Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial. Romero A, Jantus-Lewintre E, García-Peláez B, Royuela A, Insa A, Cruz P, Collazo A, Pérez Altozano J, Vidal OJ, Diz P, Cobo M, Hernández B, Vázquez Estevez S, Benítez G, Guirado M, Majem M, Bernabé R, Ortega AL, Blasco A, Bosch-Barrera J, Jurado JM, García González J, Viteri S, Garcia Giron C, Massutí B, Lopez Martín A, Rodríguez-Festa A, Calabuig-Fariñas S, Molina-Vila MÁ, **Provencio M.** *Mol Oncol.* 2021 Jan;15(1):43-56. doi: 10.1002/1878-0261.12832. Epub 2020 Nov 13. PMID: 33107189; PMCID: PMC7782072.
 122. Lung cancer patients with COVID-19 in Spain: GRAVID study. **Provencio M**, Mazarico Gallego JM, Calles A, et al. *Lung Cancer.* 2021;157:109-115. doi:10.1016/j.lungcan.2021.05.014
 123. Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. Sierra-Rodero, B., Cruz-Bermúdez, A., Nadal, E., Garitaonaindia, Y., Insa, A., Mosquera, J., Casal-Rubio, J., Dómine, M., Majem, M., Rodríguez-Abreu, D., Martínez-Martí, A., De Castro Carpeño, J., Cobo, M., López Vivanco, G., Del Barco, E., Bernabé Caro, R., Viñolas, N., Barneto Aranda, I., Viteri, S., Massuti, B., ... **Provencio, M.** (2021). *Journal for immunotherapy of cancer*, 9(8), e002804. <https://doi.org/10.1136/jitc-2021-002804>
 124. Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy. Casarrubios, M., Cruz-Bermúdez, A., Nadal, E., Insa, A., García Campelo, M. D. R., Lázaro, M., Dómine, M., Majem, M., Rodríguez-Abreu, D., Martínez-Martí, A., de Castro-Carpeño, J., Cobo, M., López-Vivanco, G., Del Barco, E., Bernabé Caro, R., Viñolas, N., Barneto Aranda, I., Viteri, S., Massuti, B., Barquín, M., ... **Provencio, M.** (2021). *Clinical cancer research : an official journal of the American Association for Cancer Research*, 27(21), 5878–5890. <https://doi.org/10.1158/1078-0432.CCR-21-1200>.
 125. Long-term follow-up of patients with nodular lymphocyte predominant Hodgkin lymphoma: A report from the Spanish Lymphoma Oncology Group. Núñez-García, B., Rodríguez-Pertierra, M., Sequero, S., Carvajal, L. G., Ruano-Ravina, A., Aguiar, D., Gumá, J., Blanco, C. Q., García Arroyo, F. R., Garitaonaindia, Y., Provencio, Z., Calvo, V., González-San Segundo, C., & **Provencio, M.** (2021). *Hematological oncology*, 39(4), 506–512.

<https://doi.org/10.1002/hon.2835>.

126. Cancer and SARS-CoV-2 Infection: A Third-Level Hospital Experience. Calvo, V., Fernandez-Cruz, A., Nuñez, B., Blanco, M., Morito, A., Martínez, M., Traseira, C., Garitaonandía, Y., Aguado, R., Ramos, A., Royuela, A., Franco, F. F., & Provencio, M. (2021). *Clinical epidemiology*, 13, 317–324. <https://doi.org/10.2147/CLEP.S308437>.
127. Lower Survival and Increased Circulating Suppressor Cells in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Deficit of Vitamin D Levels Using R-GDP Plus Lenalidomide (R2-GDP): Results from the R2-GDP-GOTEL Trial. Jiménez-Cortegana C, Sánchez-Martínez PM, Palazón-Carrión N, Nogales-Fernández E, Henao-Carrasco F, Martín García-Sancho A, Rueda A, **Provencio M**, de la Cruz-Merino L, Sánchez-Margalet V. *Cancers* (Basel). 2021 Sep 15;13(18):4622. doi: 10.3390/cancers13184622. PMID: 34572849; PMCID: PMC8471526.
128. R-Score: A New Parameter to Assess the Quality of Variants' Calls Assessed by NGS Using Liquid Biopsies. Serna-Blasco, R., Sánchez-Herrero, E., Berrocal Renedo, M., Calabuig-Fariñas, S., Molina-Vila, M. Á., **Provencio, M.**, & Romero, A. (2021). *Biology*, 10(10), 954. <https://doi.org/10.3390/biology10100954>.
129. Are there differences by sex in lung cancer characteristics at diagnosis? -a nationwide study. Ruano-Ravina, A., **Provencio, M.**, Calvo de Juan, V., Carcereny, E., Estival, A., Rodríguez-Abreu, D., Benítez, G., López-Castro, R., Belver, M., Guirado-Risueño, M., Guirao-Rubio, C., Blasco, A., Massutí, B., Ortega, A. L., Cobo, M., Mosquera-Martínez, J., Aguado de la Rosa, C., Bosch-Barrera, J., Sánchez-Gastaldo, A., Del Barco Morillo, E., ... Oramas, J. (2021). *Translational lung cancer research*, 10(10), 3902–3911. <https://doi.org/10.21037/tlcr-21-559>
130. Representativeness of the Spanish Thoracic Tumour Registry. Comparison of sociodemographic data with other national registries. Candal-Pedreira C, Ruano-Ravina A, Carcereny E, Rodríguez-Abreu D, Guirado-Risueño M, López-Castro R, Massutí B, Blasco A, Ortega AL, **Provencio M**. *Gac Sanit*. 2022 May 27:S0213-9111(22)00101-7. doi: 10.1016/j.gaceta.2022.02.013. Online ahead of print.
131. SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry. González-Cao M, Puértolas T, Martínez-Vila C, et al. *Clin and Translational Oncology*. 24 December 2022.
132. Chronodisruption and Ambulatory Circadian Monitoring in Cancer Patients: Beyond the Body Clock. Almaida-Pagan PF, Torrente M, Campos M, **Provencio M**, Madrid JA, Franco F, Morilla

- BR, Cantos B, Sousa PA, Madrid MJM, Pimentao J, Rol MÁ. Curr Oncol Rep. 2022 Feb;24(2):135-149. doi: 10.1007/s11912-021-01158-z. Epub 2022 Jan 21.
133. Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study. **Provencio M**, Rodríguez-Abreu D, Ortega AL, Serrano G, Aguado C, Franco F, Gutierrez V, López Vivanco G, Guirado M, Benítez G, Estival A, Calvo V, Jiménez B, Arasanz H, Coves J, Majem M, Massutí B, Vázquez S, Juan-Vidal O, Collazo-Lorduy A, Gozávez CL, Del Barco E, Rosero A, Bosch-Barrerra J, Moreno MA, Mielgo-Rubio X, Villa JC, López-Martin A, Córdoba JF, de Asís Aparisi F, Zafra M, Mosquera J, Pérez Altozano J, Nadal E, Catot S, Balsalobre J, de Portugal T, Martín P, Cuesta de Juan S, Cobo M. Transl Lung Cancer Res. 2022 Jan;11(1):53-63. doi: 10.21037/tlcr-21-504.
 134. A simple immunoassay for extracellular vesicle liquid biopsy in microliters of non-processed plasma Campos-Silva C, Cáceres-Martell Y, Sánchez-Herrero E, Sandúa A, Beneitez-Martínez A, González Á, **Provencio M**, Romero A, Jara-Acevedo R, Yáñez-Mó M, Valés-Gómez M.. J Nanobiotechnology. 2022 Feb 8;20(1):72. doi: 10.1186/s12951-022-01256-5.
 135. Fruits and Vegetables and Lung Cancer Risk in Never Smokers. A Multicentric and Pooled Case-Control Study. García-Lavandeira JA, Ruano-Ravina A, Torres-Durán M, Parente-Lamelas I, **Provencio M**, Varela-Lema L, Fernández-Villar A, Piñeiro M, Barros-Dios JM, Pérez-Ríos M. Nutr Cancer. 2022;74(2):613-621. doi: 10.1080/01635581.2021.1918732. Epub 2021 Aug 25.
 136. ALK-Fusion Transcripts Can Be Detected in Extracellular Vesicles (EVs) from Nonsmall Cell Lung Cancer Cell Lines and Patient Plasma: Toward EV-Based Noninvasive Testing. Sánchez-Herrero E, Campos-Silva C, Cáceres-Martell Y, Robado de Lope L, Sanz-Moreno S, Serna-Blasco R, Rodríguez-Festa A, Ares Trotta D, Martín-Acosta P, Patiño C, Coronado MJ, Beneitez A, Jara R, Lago-Baameiro N, Camino T, Cruz-Bermúdez A, Pardo M, González-Rumayor V, Valés-Gómez M, **Provencio M**, Romero A. Clin Chem. 2022 Mar 28:hvac021. doi: 10.1093/clinchem/hvac021
 137. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. Forde, P. M., Spicer, J., Lu, S., **Provencio, M.**, Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., Kerr, K., Wang, C., Ciuleanu, T. E., Saylor, G. B., Tanaka, F., Ito, H., Chen, K. N., Liberman, M., Vokes, E. E., Taube, J. M., ... CheckMate 816 Investigators (2022). The New England journal of medicine, 386(21), 1973–1985. <https://doi.org/10.1056/NEJMoa2202170>
 138. To ask, or not to mask. Current Trends in Internal Medicine. Torrente M, **Provencio M**, Sousa PA. Doi: 10.29011/2638-003X.100055. 2022.

139. Treatment Sequencing in Resectable Lung Cancer: The Good and the Bad of Adjuvant Versus Neoadjuvant Therapy. **Provencio M**, Calvo V, Romero A, Spicer JD, Cruz-Bermúdez A. *Am Soc Clin Oncol Educ Book*. 2022 Apr;42:1-18. doi: 10.1200/EDBK_358995.
140. Does the Age of Inclusion in Lung Cancer Screening Studies Overestimate the Benefits? Candal-Pedreira C, Ruano-Ravina A, **Provencio M**, Fernández-Villar A, Pérez-Ríos M. *J Thorac Oncol*. 2022 Jun;17(6):e59-e61. doi: 10.1016/j.jtho.2021.12.010.
141. Sleeve resection after neoadjuvant chemoimmunotherapy in the treatment of locally advanced non-small cell lung cancer. Dai J, Zhu X, Li D, Huang Y, Liu X, He W, Duan L, Zhao D, Zhu Y, Chen C, **Provencio M**, Ramirez RA, Antonoff MB, Wu C, Jiang G. *Transl Lung Cancer Res*. 2022 Feb;11(2):188-200. doi: 10.21037/tlcr-22-56.
142. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). **Provencio M**, Serna-Blasco R, Nadal E, Insa A, García-Campelo MR, Casal Rubio J, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Pereira E, Royuela A, Calvo V, Martín-López J, García-García F, Casarrubios M, Franco F, Sánchez-Herrero E, Massuti B, Cruz-Bermúdez A, Romero A. *J Clin Oncol*. 2022 May 16;JCO2102660. doi: 10.1200/JCO.21.02660. Online ahead of print.
143. Analysis of the metabolic proteome of lung adenocarcinomas by reverse-phase protein arrays (RPPA) emphasizes mitochondria as targets for therapy. Torresano L, Santacatterina F, Domínguez-Zorita S, Nuevo-T Liquid Biopsy in Follicular Lymphomaapioles C, Núñez-Salgado A, Esparza-Moltó PB, González-Llorente L, Romero-Carramiñana I, Núñez de Arenas C, Sánchez-Garrido B, Nájera L, Salas C, **Provencio M**, Cuezva JM. *Oncogenesis*. 2022 May 9;11(1):24. doi: 10.1038/s41389-022-00400-y.
144. Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC. Rocha P, Zhang J, Laza-Briviesca R, Cruz-Bermúdez A, Bota-Rabassedas N, Sanchez-Espiridon B, Yoshimura K, Behrens C, Lu W, Tang X, Pataer A, Parra ER, Haymaker C, Fujimoto J, Swisher SG, Heymach JV, Gibbons DL, Lee JJ, Sepesi B, Cascone T, Solis LM, **Provencio M**, Wistuba II, Kadara H. *Clin Cancer Res*. 2022 Jun 1;28(11):2461-2473. doi: 10.1158/1078-0432.CCR-21-3207.
145. Negation and uncertainty detection in clinical texts written in Spanish: a deep learning-based approach. Solarte Pabón O, Montenegro O, Torrente M, Rodríguez González A, **Provencio M**,

Menasalvas E. PeerJ Comput Sci. 2022 Mar 7;8:e913. doi: 10.7717/peerj-cs.913. eCollection 2022.

146. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis. Dafni U, Soo RA, Peters S, Tsourti Z, Zygoura P, Vervita K, Han JY, De Castro J, Coate L, Früh M, Hashemi SMS, Nadal E, Carcereny E, Sala MA, Bernabé R, **Provencio M**, Cuffe S, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel RA. ESMO Open. 2022 Jun;7(3):100507. doi: 10.1016/j.esmoop.2022.100507.
147. Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial. Felip E, Smit EF, Molina-Vila MA, Dafni U, Massuti B, Berghmans T, de Marinis F, Passiglia F, Dingemans AC, Cobo M, Viteri S, Britschgi C, Cuffe S, **Provencio M**, Merkelbach-Bruse S, Andriakopoulou C, Kammler R, Ruepp B, Roschitzki-Voser H, Peters S, Wolf J, Stahel R. Lung Cancer 12 August, 2022.
148. Genetic and phenotypic characterization of HIV-associated aggressive B-cell non-Hodgkin lymphomas, that do not occur specifically in this population: diagnostic and prognostic implications. Baptista MJ, Tapia G, Muñoz-Marmol AM, Muncunill J, Garcia O, Montoto S, Gribben JG, Calaminici M, Martinez A, Veloza L, Martínez-Trillos A, Aldamiz T, Menarguez J, Terol MJ, Ferrandez A, Alcoceba M, Briones J, González-Barca E, Climent F, Muntañola A, Moraleda JM, **Provencio M**, Abrisqueta P, Abella E, Colomo L, García-Ballesteros C, Garcia-Caro M, Sancho JM, Ribera JM, Mate JL, Navarro JT. Histopathology. 2022 Sep. DOI: 10.1111/his.14798. PMID: 36109172.
149. Molecular divergence upon EGFR-TKI resistance could be dependt on the exón location of the original EGFR sensitizing mutation. Serna-Blasco R, Sanchez E, Robado L, **Provencio M**. Cancers 2022; 14, 4446.
150. International expert consensus on immunotherapy for early-stage non-small cell lung cancer. Liang W, Cai K, Cao Q, Chen C, Chen H, Chen J, Chen KN, Chen Q, Chu T, Dong Y, Fan J, Fang W, Fu J, Fu X, Gao S, Ge D, Geng G, Geng Q, He J, Hu J, Hu J, Hu WD, Jiang F, Jiang T, Jiao W, Li HC, Li Q, Li S, Li S, Li X, Liao YD, Liu C, Liu H, Liu Y, Lu Z, Luo Q, Ma H, Pan X, Qiao G, Ren S, Shen W, Song Y, Sun D, Wang G, Wang J, Wang M, Wang Q, Wang WX, Wei L, Wu M, Wu N, Xia H, Xu SD, Yang F, Yang K, Yang Y, Yu F, Yu ZT, Yue DS, Zhang L, Zhang W, Zhang Z, Zhao G, Zhao J, Zhao X, Zhou C, Zhou Q, Zhu K, Zhu Y, Hida T, Dempke WCM, Rossi A, de Perrot M, Ramirez RA, **Provencio M**, Lee JM, Passaro A, Spaggiari L, Spicer J, Girard N, Forde PM, Mok TSK,

- Cascone T, He J. Transl Lung Cancer Res. 2022 Sep;11(9):1742-1762. doi: 10.21037/tlcr-22-617. PMID: 36248334; PMCID: PMC9554679.
151. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy. Casarrubios M, **Provencio M**, Nadal E, et al. Journal for Immunotherapy of Cancer 2022: 10:e005320.
152. Understanding prognosis and survival outcomes in patients with early-stage non-small-cell lung cancer. Torrente M, Sousa PA, Franco F, Guerreiro G, Sousa A, Parejo C, Pimentao J, **Provencio M**. Clin Med (Lond). 2022 Jul;22(Suppl 4):38-40. doi: 10.7861/clinmed.22-4-s38. PMID: 36220219 No abstract available.
153. Safety of First-line nivolumab plus ipilimumab in patients with metastatic NSCLC: A pooled analysis of CheckMate 227, Checkmate 568, and CheckMate 817. Paz-Ares LG, Ciuleanu TE, Pluzanski A, Lee JS, Gainor JF, Otterson GA, Audigier-Valette C, Ready N, Schenker M, Linardou H, Caro RB, **Provencio M**, Zurawski B, Lee KH, Kim SW, Caserta C, Ramalingam SS, Spigel DR, Brahmer JR, Reck M, O'Byrne KJ, Girard N, Popat S, Peters S, Memaj A, Nathan F, Aanur N, Borghaei H. Journal Thoracic Oncology, 2022, doi.org/10.1016/j.jtho.2022.08.014.
154. Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors. Torrente M, Blanco M, Franco F, Garitaonandia Y, Calvo V, Collazo-Lorduy A, Gutierrez L, Sánchez J, González del Alba A, Hernández R, Méndez M, Cantos B, Núñez B, Sousa P, **Provencio M**. Frontiers in Cardiovascular Medicine, 01 december 2022. Doi: 10.3389/fcvm.2022.1062858.
155. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. Soo, R. A., Han, J. Y., Dafni, U., Cho, B. C., Yeo, C. M., Nadal, E., Carcereny, E., de Castro, J., Sala, M. A., Bernabé, R., Coate, L., **Provencio Pulla, M.**, Garcia Campelo, R., Cuffe, S., Hashemi, S. M. S., Früh, M., Massuti, B., Garcia-Sanchez, J., Dómine, M., Majem, M., ... ETOP 10-16 BOOSTER Collaborators (2022). Annals of oncology : official journal of the European Society for Medical Oncology, 33(2), 181–192. <https://doi.org/10.1016/j.annonc.2021.11.010>.
156. Small Cell Lung Cancer-A Neglected Disease With More Data Needed. Ruano-Raviña, A., **Provencio-Pulla, M.**, & Pérez-Ríos, M. (2022). JAMA network open, 5(3), e224837. <https://doi.org/10.1001/jamanetworkopen.2022.4837>

157. An Artificial Intelligence-Based Tool for Data Analysis and Prognosis in Cancer Patients: Results from the Clarify Study. Torrente, M., Sousa, P. A., Hernández, R., Blanco, M., Calvo, V., Collazo, A., Guerreiro, G. R., Núñez, B., Pimentao, J., Sánchez, J. C., Campos, M., Costabello, L., Novacek, V., Menasalvas, E., Vidal, M. E., & **Provencio, M.** (2022). *Cancers*, 14(16), 4041. <https://doi.org/10.3390/cancers14164041>
158. Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study. Candal-Pedreira, Cristina; Ruano-Ravina, Alberto; Calvo de Juan, Virginia; et al; (25/25) **Provencio, Mariano**. 2023. *ERJ OPEN RESEARCH*. 9. <https://doi.org/10.1183/23120541.00468-2023>
159. Machine-Learning-Assisted Recurrence Prediction for Early-Stage Non-Small-Cell Lung Cancer Patients. Adrianna Janik; Maria Torrente; Luca Costabello; et al; (17/17) **Mariano Provencio**. 2023. *Journal Clinical Cancer Informatics*. <https://doi.org/10.1200/CCI.22.00062>
160. Is there a role for first generation TKIs in adjuvant setting of EGFR mutated early NSCLC?. A.V. Ospina; (2/2) **M. Provencio**. 2023 *Chinese clinical oncology*. cco-23-27. <https://doi.org/10.21037/cco-23-27>
161. Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study. Ismael Fernández-Miranda; Lucía Pedrosa; Marta Llanos; et al; Margarita Sánchez-Beato; (19/20) **Mariano Provencio**. 2023. *Clinical cancer research: an official journal of the American Association for Cancer Research*. 29.1. <https://doi.org/10.1158/1078-0432.CCR-22-1654>.
162. Clinical factors influencing long-term survival in a real-life cohort of early stage non-small-cell lung cancer patients in Spain. Maria Torrente; Pedro Sousa; Gracinda Guerreiro; et al; (10/10) **Mariano Provencio**. 2023. *Frontiers in Oncology*. <https://doi.org/10.3389/fonc.2023.1074337>
163. Differential organ-specific tumor response to first-line immune checkpoint inhibitor therapy in non-small cell lung cancer—a retrospective cohort study. Qi Wang; Yujia Fang; Chunyu Li; Tracy L. Leong; (5/8) **Mariano Provencio**; In-Jae Oh; Zhemin Zhang; Chunxia Su. 2023. *Translational Lung Cancer Research*. 12-2, pp.312-321. ISSN 2226-4477. <https://doi.org/10.21037/tlcr-23-83>
164. Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial. (1/22) **Provencio M (AC)**; Ortega AL; Coves-Sarto J; et al;

- Cruz-Bermúdez A. 2023. JAMA Oncology. JAMA Oncology. 9-3, pp.344-353.
<https://doi.org/10.1001/jamaoncol.2022.5959>
165. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer. (1/30) **Provencio M** (AC); Ernest N; Gonzalez-Larriba JL; et al; Romero A. 2023. New England Journal of Medicine. NEJM. 389.6.
<https://doi.org/10.1056/NEJMoa2215530>
 166. Predictive value of radiological response, pathological response and relapse-free survival for overall survival in neoadjuvant immunotherapy trials: pooled analysis of 29 clinical trials. Runcong Nie; Foping Chen; (3/13) **Mariano Provencio**; et al; Muyan Cai. 2023. Eur J Cancer. ISSN 0959-8049. <https://doi.org/10.1016/j.ejca.2023.03.010>
 167. Long-term outcomes in Hodgkin lymphoma survivors. Temporary trends and comparison with general population. Núñez-García B, Clemente MB, Sánchez JC, Royuela A, Ibargüen BCS, Méndez M, López-Ibor JV, Martínez M, Traseira C, Garitaonandia Y, Aguado R, Calvo V, Torrente M, Parejo C, Provencio Z, **Provencio M**. Hematol Oncol. 2023 Aug;41(3):407-414. doi: 10.1002/hon.3131. Epub 2023 Mar 19. PMID: 36934306.
 168. Detecting ALK, ROS1, and RET fusions and the MET Δ ex14 splicing variant in liquid biopsies of non-small-cell lung cancer patients using RNA-based techniques. Giménez-Capitán A, Sánchez-Herrero E, Robado de Lope L, Aguilar-Hernández A, Sullivan I, Calvo V, Moya-Horno I, Viteri S, Cabrera C, Aguado C, Armiger N, Valarezo J, Mayo-de-Las-Casas C, Reguart N, Rosell R, (16/18) **Provencio M**, Romero A, Molina-Vila MA. Mol Oncol. 2023 Sep;17(9):1884-1897. doi: 10.1002/1878-0261.13468. Epub 2023 Jun 6. PMID: 37243883; PMCID: PMC10483610.
 169. ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma. Zinzani PL; Mayer J; Flowers CR; et al; Delarue R; (14/26) **Provencio Pulla M**. 2023. J Clin Oncol. <https://doi.org/10.1200/JCO.23.00775>
 170. Immunogenicity of COVID-19 vaccines in lung cancer patients. (1/29) **M Provencio**; A Estival; F Franco; et al; E Del Barco. 2023. Lung Cancer. 184-107323. <https://doi.org/10.1016/j.lungcan.2023.107323>
 171. Difficulties on the access to innovative targeted therapies for lung cancer in Spain. Calvo V, Camps C, Carcereny E, Cobo M, Dómine M, García Campelo MR, González Larriba JL, Guirado M, Hernando-Trancho F, Massutí B, Nadal E, Rodríguez-Abreu D, Sánchez A, Sullivan IG, (15/17) **Provencio M**; Spanish Lung Cancer Group (SLCG/GECP). Clin Transl Oncol. 2024

- Mar;26(3):597-612. doi: 10.1007/s12094-023-03303-5. Epub 2023 Aug 31. PMID: 37651020; PMCID: PMC10869378.
172. A genetic profiling guideline to support diagnosis and clinical management of lymphomas. Sánchez-Beato M, Méndez M, Guirado M, Pedrosa L, Sequero S, Yanguas-Casás N, de la Cruz-Merino L, Gálvez L, Llanos M, García JF, (11/11) **Provencio M**. Clin Transl Oncol. 2024 May;26(5):1043-1062. doi: 10.1007/s12094-023-03307-1. Epub 2023 Sep 6. PMID: 37672206; PMCID: PMC11026206.
173. Association between pathologic response and survival after neoadjuvant therapy in lung cancer. Deutsch JS, Cimino-Mathews A, Thompson E, (4/24) **Provencio M**, Forde PM, Spicer J, Girard N, Wang D, Anders RA, Gabrielson E, Illei P, Jedrych J, Danilova L, Sunshine J, Kerr KM, Tran M, Bushong J, Cai J, Devas V, Neely J, Balli D, Cottrell TR, Baras AS, Taube JM. Nat Med. 2024 Jan;30(1):218-228. doi: 10.1038/s41591-023-02660-6. Epub 2023 Oct 30. PMID: 37903504; PMCID: PMC10803255.
174. Sexual dysfunction in patients with cancer, a challenge in oncology practice: results of the CLARIFY project. Ospina-Serrano AV, Maximiano C, Cantos B, Torrente M, Mendez M, Sanchez JC, Calvo V, Collazo-Lorduy A, Blanco M, Nuñez B, Triana I, Parejo C, Martinez P, Duma N, (15/15) **Provencio-Pulla M**. Clin Transl Oncol. 2024 May;26(5):1147-1156. doi: 10.1007/s12094-023-03332-0. Epub 2023 Nov 2. PMID: 37917247.
175. Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial. Postel-Vinay S, Coves J, Texier M, Aldea M, Gazzah A, Dómine M, Planchard D, De Las Peñas R, Sala Gonzalez MA, Viteri S, Perez J, Ortega AL, Moran T, Camps C, Lopez-Martin A, (16/20) **Provencio M**, Soria JC, Besse B, Massuti B, Rosell R. Br J Cancer. 2024 Feb;130(3):417-424. doi: 10.1038/s41416-023-02514-5. Epub 2023 Dec 14. PMID: 38097741; PMCID: PMC10844295.
176. Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer. (1/12) **Provencio-Pulla M**, Pérez-Parente D, Olson S, Hasan H, Balea BC, Rodríguez-Abreu D, Piqueras ML, Pal N, Wilkinson S, Vilas E, Ruiz-Gracia P, Cobo-Dols M. Clin Transl Oncol. 2024 Jun;26(6):1384-1394. doi: 10.1007/s12094-023-03362-8. Epub 2024 Jan 6. PMID: 38183584; PMCID: PMC11108921.
177. A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer. Riely GJ, Smit EF, Ahn MJ, Felip E, Ramalingam SS, Tsao A, Johnson M, Gelsomino F, Esper R, Nadal

- E, Offin M, (12/25) **Provencio M**, Clarke J, Hussein M, Otterson GA, Dagogo-Jack I, Goldman JW, Morgensztern D, Alcasid A, Usari T, Wissel P, Wilner K, Pathan N, Tonkovyd S, Johnson BE. *Future Oncol.* 2024;20(16):1047-1055. doi: 10.2217/fon-2023-0859. Epub 2024 Feb 15. PMID: 38357801.
178. Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer: KEYNOTE-782. *Lung Cancer.* Bar J, Esteban E, Rodríguez-Abreu D, Aix SP, Szalai Z, Felip E, Gottfried M, (8/23) **Provencio M**, Robinson A, Fülöp A, Rao SB, Camidge DR, Speranza G, Townson SM, Kobie J, Ayers M, Dettman EJ, Hunkapiller N, McDaniel R, Jung B, Burkhardt D, Mauntz R, Csösz T. 2024 Apr;190:107506. doi: 10.1016/j.lungcan.2024.107506. Epub 2024 Feb 17. PMID: 38422883.
 179. CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma. Hontecillas-Prieto L, García-Domínguez DJ, Palazón-Carrión N, Martín García-Sancho A, Nogales-Fernández E, Jiménez-Cortegana C, Sánchez-León ML, Silva-Romeiro S, Flores-Campos R, Carnicero-González F, Ríos-Herranz E, de la Cruz-Vicente F, Rodríguez-García G, Fernández-Álvarez R, Martínez-Banaclocha N, Gumà-Padrò J, Gómez-Codina J, Salar-Silvestre A, Rodríguez-Abreu D, Gálvez-Carvajal L, Labrador J, Guirado-Risueño M, (23/30) **Provencio-Pulla M**, Sánchez-Beato M, Marylene L, Álvaro-Naranjo T, Casanova-Espinosa M, Rueda-Domínguez A, Sánchez-Margalet V, de la Cruz-Merino L *Front Immunol.* 2024 Feb 26;15:1293931. doi: 10.3389/fimmu.2024.1293931. PMID: 38469299; PMCID: PMC10926187.
 180. Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry. (1/23) **Provencio M**, Cobo M, Rodríguez-Abreu D, Carcereny E, Cantero A, Calvo V, López Castro R, Bernabé R, Bosch-Barrera J, Massutí B, García Campelo R, Sánchez-Hernández A, Laura Ortega A, Guirado M, Del Barco E, Camps C, Casal-Rubio J, Dómine M, Angeles Sala M, Padilla A, Luís González Larriba J, de Asís Aparisi F; Spanish Lung Cancer Group SLCG/GECP. *Lung Cancer.* 2024 Apr;190:107513. doi: 10.1016/j.lungcan.2024.107513. Epub 2024 Feb 29. PMID: 38432027.
 181. New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe. Houda I, Dickhoff C, Uyl-de Groot CA, Reguart N, (5/14) **Provencio M**, Levy A, Dziadziuszko R, Pompili C, Di Maio M, Thomas M, Brunelli A, Popat S,

- Senan S, Bahce I. Lancet Reg Health Eur. 2024 Mar 4;38:100840. doi: 10.1016/j.lanepe.2024.100840. PMID: 38476748; PMCID: PMC10928304.
182. Challenges and controversies in resectable non-small cell lung cancer: a clinician's perspective. Houda I, Dickhoff C, Uyl-de Groot CA, Damhuis RAM, Reguart N, (6/15) **Provencio M**, Levy A, Dziadziuszko R, Pompili C, Di Maio M, Thomas M, Brunelli A, Popat S, Senan S, Bahce I. Lancet Reg Health Eur. 2024 Mar 1;38:100841. doi: 10.1016/j.lanepe.2024.100841. PMID: 38476749; PMCID: PMC10928275.
183. Neoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis. Sorin M, Prosty C, Ghaleb L, Nie K, Katergi K, Shahzad MH, Dubé LR, Atallah A, Swaby A, Dankner M, Crump T, Walsh LA, Fiset PO, Sepesi B, Forde PM, Cascone T, (17/18) **Provencio M**, Spicer JD. JAMA Oncol. 2024 May 1;10(5):621-633. doi: 10.1001/jamaoncol.2024.0057. PMID: 38512301; PMCID: PMC10958389.
184. Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP. Ospina AV, Bolufer Nadal S, Campo-Cañaveral de la Cruz JL, González Larriba JL, Macía Vidueira I, Massutí Sureda B, Nadal E, Trancho FH, Álvarez Kindelán A, Del Barco Morillo E, Bernabé Caro R, Bosch Barrera J, Calvo de Juan V, Casal Rubio J, de Castro J, Cilleruelo Ramos Á, Cobo Dols M, Dómine Gómez M, Figueroa Almánzar S, Garcia Campelo R, Insa Mollá A, Jarabo Sarceda JR, Jiménez Maestre U, López Castro R, Majem M, Martinez-Marti A, Martínez Téllez E, Sánchez Lorente D, (29/29) **Provencio M**. Clin Transl Oncol. 2024 Jul;26(7):1647-1663. doi: 10.1007/s12094-024-03382-y. Epub 2024 Mar 26. PMID: 38530556; PMCID: PMC11178633.
185. Letter to editor response: "Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP. Controversies and Discussion". Ospina AV, Bolufer Nadal S, Massuti Sureda B, (4/4) **Provencio M**. Clin Transl Oncol. 2024 Jun 14. doi: 10.1007/s12094-024-03560-y. Epub ahead of print. PMID: 38874803.
186. Perioperative Nivolumab in Resectable Lung Cancer. Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, Tanaka F, Taube JM, Cornelissen R, Havel L, Karaseva N, Kuzdzal J, Petruzella LB, Wu L, Pujol JL, Ito H, Ciuleanu TE, de Oliveira Muniz Koch L, Janssens A, Alexandru A, Bohnet S, Moiseyenko FV, Gao Y, Watanabe Y, Coronado Erdmann C, Sathyanarayana P, Meadows-Shropshire S, Blum SI, (30/30) **Provencio Pulla M**; CheckMate 77T Investigators. N Engl J Med. 2024 May 16;390(19):1756-1769. doi: 10.1056/NEJMoa2311926. PMID: 38749033.

187. Generation and External Validation of a Histologic Transformation Risk Model for Patients with Follicular Lymphoma. Fernández-Miranda I, Pedrosa L, González-Rincón J, Espinet B, de la Cruz Vicente F, Climent F, Gómez S, Royuela A, Camacho FI, Martín-Acosta P, Yanguas-Casás N, Domínguez M, Méndez M, Colomo L, Salar A, Horcajo B, Navarro M, García-Cosío M, Piris-Villaespesa M, Llanos M, García JF, Sequero S, Mercadal S, García-Hernández S, Navarro B, Mollejo M, (27/28) **Provencio M**, Sánchez-Beato M. *Mod Pathol*. 2024 Jul;37(7):100516. doi: 10.1016/j.modpat.2024.100516. Epub 2024 May 17. PMID: 38763418.
188. Advanced non-squamous NSCLC with no actionable oncogenic driver in Spain: a cross-sectional descriptive analysis of data from the Thoracic Tumor Registry. Carcereny E, Rodriguez-Abreu D, Lopez R, Franco F, Guirado M, Massutí B, Cobo M, Blasco A, Suay G, Del Barco E, Ortega AL, Sala MA, Cordeiro P, Bernabé R, González Larriba JL, Bosch-Barrera J, Calzas J, Casal J, Padilla A, Sánchez-Hernandez A, (21/21) **Provencio M**. *Clin Transl Oncol*. 2024 Jun 11. doi: 10.1007/s12094-024-03511-7. PMID: 38862862.
189. Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer. Spicer JD, Cascone T, Wynes MW, Ahn MJ, Dacic S, Felip E, Forde PM, Higgins KA, Kris MG, Mitsudomi T, (11/21) **Provencio M**, Senan S, Solomon BJ, Tsao MS, Tsuboi M, Wakelee HA, Wu YL, Chih-Hsin Yang J, Zhou C, Harpole DH, Kelly KL. *J Thorac Oncol*. 2024 Oct;19(10):1373-1414. doi: 10.1016/j.jtho.2024.06.010. Epub 2024 Jun 18. PMID: 38901648.
190. Integrated management of stage III in nonsmall cell lung cancer: where do perioperative chemotherapy and immunotherapy fit? Collazo-Lorduy A, Blanco M, Calvo V, (4/4) **Provencio M**. *Curr Opin Pulm Med*. 2024 Jul 1;30(4):346-351. doi: 10.1097/MCP.0000000000001079. Epub 2024 May 7. PMID: 38712693.
191. Clinical approach for managing patients with unexpected CDH1 mutations: A case report. Garitaonandia Y, Méndez M, Valentín F, Gutiérrez L, de Tejada AH, Sánchez Ruiz A, (7/8) **Provencio M**, Romero A. *Mol Genet Genomic Med*. 2024 Jul;12(7):e2496. doi: 10.1002/mgg3.2496. PMID: 39056403; PMCID: PMC11273211.
192. Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer. Peressini M, Garcia-Campelo R, Massuti B, Martí C, Cobo M, Gutiérrez V, Dómine M, Fuentes J, Majem M, de Castro J, Córdoba JF, Diz MP, Isla D, Esteban E, Carcereny E, Vila L, Moreno-Vega A, Ros S, Moreno A, García FJ, Huidobro G, Aguado C, Cebey-López V, Valdivia J, Palmero R, Lianes P,

- López-Brea M, Vidal OJ, (29/43) **Provencio M**, Arriola E, Baena J, Herrera M, Bote H, Molero M, Adradas V, Ponce-Aix S, Nuñez-Buiza A, Ucero Á, Hernandez S, Lopez-Rios F, Conde E, Paz-Ares L, Zugazagoitia J. Clin Cancer Res. 2024 Jul 15;30(14):3036-3049. doi: 10.1158/1078-0432.CCR-24-0104. PMID: 38630755.
193. Lung cancer risk associated with occupations in women: a pooling study. Torres-Cadavid E, Pérez-Ríos M, Candal-Pedreira C, Guerra-Tort C, Rey-Brandariz J, (6/8) **Provencio-Pulla M**, Kelsey K, Ruano-Ravina A. Occup Med (Lond). 2024 Jul 29;74(5):348-354. doi: 10.1093/occmed/kqae050. PMID: 39024516.
194. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with leptomeningeal metastases harboring targetable mutations. Ji X, Jiang R, Liu T, (4/7) **Provencio M**, Lee SC, Zhan Q, Zhou X. Transl Lung Cancer Res. 2024 Jul 30;13(7):1695-1707. doi: 10.21037/tlcr-24-477. Epub 2024 Jul 18. PMID: 39118876; PMCID: PMC11304138.
195. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC (1/35) **Provencio M**, Robado de Lope L, Serna-Blasco R, Nadal E, Diz Tain P, Massuti B, González-Larriba JL, Insa A, Sánchez-Hernández A, Casal-Rubio J, García-Campelo R, Sequero López S, Rogado J, Martínez-Martí A, Bosch-Barrera J, Bernabé R, Vázquez Estévez S, Ponce S, de Castro J, Coves Sarto J, Reguart N, Dómine M, Aguilar A, Majem M, Estival A, Peña Cabia S, López Martín A, Sala González MÁ, Cobo M, Camps C, Barneto I, Calvo V, Collazo-Lorduy A, Cruz-Bermúdez A, Romero A.. Lung Cancer. 2024 Aug;194:107865. doi: 10.1016/j.lungcan.2024.107865. Epub 2024 Jun 26. PMID: 38945004.
196. Reply. The New England journal of medicine. Cascone, Tina; Spicer, Jonathan D; (3/3) **Provencio Pulla, Mariano**. 2024. Perioperative Nivolumab in Resectable Lung Cancer. 391-6, pp.573-574. ISSN 1533-4406. <https://doi.org/10.1056/NEJMc2407267>
197. Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial. **Provencio, M.**, Nadal, E., Insa, A., García Campelo, R., Casal, J., Dómine, M., Massuti, B., Majem, M., Rodríguez-Abreu, D., Martínez-Martí, A., de Castro, J., Gómez de Antonio, D., Macia, I., Figueroa, S., Fernández Vago, L., Calvo, V., Palmero, R., Sierra-Rodero, B., Martínez-Toledo, C., Molina-Alejandro, M., ... Cruz-Bermúdez, A. (2024). The Lancet. Oncology, 25(11), 1453–1464. [https://doi.org/10.1016/S1470-2045\(24\)00498-4](https://doi.org/10.1016/S1470-2045(24)00498-4).

198. Promoting responsible scientific research: integrating retractions into the ORCID profile. Candal-Pedreira C, Ruano-Ravina A, Pérez-Ríos M, **Provencio M**. *J Clin Epidemiol*. 2024 Aug;172:111403. doi: 10.1016/j.jclinepi.2024.111403. Epub 2024 May 28. PMID: 38815635.
199. Family history of cancer and lung cancer: Utility of big data and artificial intelligence for exploring the role of genetic risk. Calvo V, Niazmand E, Carcereny E, Rodriguez-Abreu D, Cobo M, López-Castro R, Guirado M, Camps C, Laura Ortega A, Bernabé R, Massutí B, Garcia-Campelo R, Del Barco E, Luis González-Larriba J, Bosch-Barrera J, Martínez M, Torrente M, Vidal ME, **Provencio M**. *Lung Cancer*. 2024 Sep;195:107920. doi: 10.1016/j.lungcan.2024.107920. Epub 2024 Aug 9. PMID: 39137596.
200. Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial. Michels S, Massutí B, Vasylyv I, Stratmann J, Frank J, Adams A, Felip E, Grohé C, Rodriguez-Abreu D, Bischoff H, Carcereny I Costa E, Corral J, Pereira E, Fassunke J, Fischer RN, Insa A, Koleczko S, Nogova L, Reck M, Reutter T, Riedel R, Schaufler D, Scheffler M, Weisthoff M, **Provencio M**, Merkelbach-Bruse S, Hellmich M, Sebastian M, Büttner R, Persigehl T, Rosell R, Wolf J. *ESMO Open*. 2024 Feb;9(2):102237. doi: 10.1016/j.esmoop.2024.102237. Epub 2024 Feb 12. PMID: 38350336; PMCID: PMC10937203.
201. A Descriptive Study of 103 Primary Cutaneous B-Cell Lymphomas: Clinical and Pathological Characteristics and Treatment from the Spanish Lymphoma Oncology Group (GOTEL). Martínez-Banaclocha N, Martínez-Madueño F, Caballé B, Badia J, Blanes M, Bujanda DA, Calvo V, Gómez Codina J, Blanco CQ, Espinosa P, Lavernia J, Arroyo FRG, Risueño MG, Llorca C, Cumeras R, **Pulla MP**, Gumà J. *Cancers (Basel)*. 2024 Mar 3;16(5):1034. doi: 10.3390/cancers16051034. PMID: 38473391; PMCID: PMC10931196.
202. Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer. Molina-Alejandro M, Perea F, Calvo V, Martinez-Toledo C, Nadal E, Sierra-Rodero B, Casarrubios M, Casal-Rubio J, Martinez-Martí A, Insa A, Massuti B, Viteri S, Barneto Aranda I, Rodriguez-Abreu D, de Castro J, Martínez JM, Cobo M, Wistuba II, Parra ER, Martín-López J, Megías D, Muñoz-Viana R, Garrido F, Aptsiauri N, Ruiz-Cabello F, **Provencio M**, Cruz-Bermúdez A. *J Immunother Cancer*. 2024 Oct 20;12(10):e009762. doi: 10.1136/jitc-2024-009762. PMID: 39428126; PMCID: PMC11492944.
203. Optimizing genetic testing strategy for suspected attenuated adenomatous polyposis: effective solutions in public health systems. García-Simón N, Valentín F, Royuela A, Hidalgo-

- Calero B, Blázquez-Martín R, de-Miguel-Reyes M, Sánchez-Zapardiel JM, Adán-Merino L, Rodríguez-Festa A, Gallego-Gil P, Mediavilla-Medel P, Quiñonero-Moreno L, Gutiérrez L, Herreros-de-Tejada A, Sánchez A, **Provencio M**, Romero A. Clin Transl Oncol. 2024 Dec 11. doi: 10.1007/s12094-024-03811-y. Epub ahead of print. PMID: 39661238.
204. A lung cancer diagnosis and treatment dataset with geno- and phenotypical characteristics of the patient. Ríos-Sánchez B, Viguera G, García A, Gómez-Bravo D, Menasalvas E, Torrente M, Parejo C, Aisopos F, Vogiatzis D, Purohit D, **Provencio M**, Vidal ME, Rodríguez-González A. Data Brief. 2024 Nov 23;57:111167. doi: 10.1016/j.dib.2024.111167. PMID: 39736907; PMCID: PMC11683279.
205. ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial. Soo RA, Dafni U, Han JY, Cho BC, Nadal E, Yeo CM, Carcereny E, de Castro J, Sala MA, Coate L, **Provencio M**, Britschgi C, Vagenknecht P, Dimopoulou G, Kammler R, Finn SP, Peters S, Stahel RA; ETOP 10-16 BOOSTER Collaborators. Clin Cancer Res. 2024 Nov 15;30(22):5180-5191. doi: 10.1158/1078-0432.CCR-24-0932. PMID: 39250635.
206. DSTYK Inhibition Sensitizes NSCLC to Taxane-Based Chemotherapy. Echepare M, Picabea B, Arricibita A, Teixeira Á, Pasquier A, Zanduetta C, Otegui N, Santamaría E, Fernández-Irigoyen J, Romero O, Sanchez-Céspedes M, Lecanda F, Hernández J, Felipe E, Cruz-Bermúdez A, **Provencio M**, Gentili M, Facchinetti F, Roz L, Montuenga LM, Valencia K. J Thorac Oncol. 2024 Nov 12:S1556-0864(24)02438-9. doi: 10.1016/j.jtho.2024.11.003. Epub ahead of print. PMID: 39536877.
207. NSSC: a neuro-symbolic AI system for enhancing accuracy of named entity recognition and linking from oncologic clinical notes. García-Barragán Á, Sakor A, Vidal ME, Menasalvas E, Gonzalez JCS, **Provencio M**, Robles V. Med Biol Eng Comput. 2024 Nov 1. doi: 10.1007/s11517-024-03227-4. Epub ahead of print. PMID: 39485651.
208. Analysis of Diagnostic Delay and its Impact on Lung Cancer Survival: Results From the Spanish Thoracic Tumor Registry. Candal-Pedreira C, Ruano-Ravina A, Calvo de Juan V, Cobo M, Cantero A, Rodríguez-Abreu D, Estival A, Carcereny E, Hernandez A, López Castro R, Medina A, García Campelo R, Fernández Bruno M, Barnabé R, Bosch-Barrera J, Massutí B, Dómine M, Camps C, Ortega AL, (20/20) **Provencio M**. Arch Bronconeumol. 2024 Oct;60 Suppl 2:S38-S45. English, Spanish. doi: 10.1016/j.arbres.2024.07.006. Epub 2024 Jul 15. PMID: 39068056.

209. Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients. Candal-Pedreira C, Ruano-Ravina A, Calvo de Juan V, Cobo M, Trigo JM, Rodríguez-Abreu D, Estival A, Carcereny E, Cucurull M, López Castro R, Medina A, García Campelo R, Cordeiro González P, Sánchez-Gastaldo A, Bosch-Barrera J, Massutí B, Dómine M, Camps C, Ortega AL, Sánchez-Hernández A, Guirado Risueño M, Del Barco Morillo E, Garrido Fernández A, (24/24) **Provencio M**. Arch Bronconeumol. 2024 Feb;60(2):88-94. English, Spanish. doi: 10.1016/j.arbres.2023.12.005. Epub 2023 Dec 18. PMID: 38160163.
210. Adoptive cell therapies in thoracic malignancies: a comprehensive review. Garitaonandia Y, Martínez-Cutillas M, Uribarren M, Redondo I, Calvo V, Serna-Blasco R, **Provencio M**. Clin Transl Oncol. 2025 Jan 9. doi: 10.1007/s12094-024-03834-5. Epub ahead of print. PMID: 39789380.